

Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling

Reviewed Preprint

Revised by authors after peer review.

[About eLife's process](#)

Reviewed preprint version 2

May 1, 2024 (this version)

Reviewed preprint version 1

November 23, 2023

Posted to preprint server

August 25, 2023

Sent for peer review

August 23, 2023

Henning Mühlenbeck, Yuko Tsutsui, Mark A. Lemmon, Kyle W. Bender , Cyril Zipfel 

Institute of Plant and Microbial Biology, Zürich-Basel Plant Science Center, University of Zürich, 8008 Zürich, Switzerland • Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA • Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT, 06516, USA • The Sainsbury Laboratory, University of East Anglia, Norwich Research Park, NR4 7UH Norwich, U.K

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Transmembrane signaling by plant receptor kinases (RKs) has long been thought to involve reciprocal trans-phosphorylation of their intracellular kinase domains. The fact that many of these are pseudokinase domains, however, suggests that additional mechanisms must govern RK signaling activation. Non-catalytic signaling mechanisms of protein kinase domains have been described in metazoans, but information is scarce for plants. Recently, a non-catalytic function was reported for the leucine-rich repeat (LRR)-RK subfamily XIIa member EFR (ELONGATION FACTOR TU RECEPTOR) and phosphorylation-dependent conformational changes were proposed to regulate signaling of RKs with non-RD kinase domains. Here, using EFR as a model, we describe a non-catalytic activation mechanism for LRR-RKs with non-RD kinase domains. EFR is an active kinase, but a kinase-dead variant retains the ability to enhance catalytic activity of its co-receptor kinase BAK1/SERK3 (BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED KINASE 1/SOMATIC EMBRYOGENESIS RECEPTOR KINASE 3). Applying hydrogen-deuterium exchange mass spectrometry (HDX-MS) analysis and designing homology-based intragenic suppressor mutations, we provide evidence that the EFR kinase domain must adopt its active conformation in order to activate BAK1 allosterically, likely by supporting α C-helix positioning in BAK1. Our results suggest a conformational toggle model for signaling, in which BAK1 first phosphorylates EFR in the activation loop to stabilize its active conformation, allowing EFR in turn to allosterically activate BAK1.

eLife assessment

This manuscript reports **important** in vitro biochemical and in planta experiments to study the receptor activation mechanism of plant membrane receptor kinase complexes with non-catalytic intracellular kinase domains. Several lines of evidence **convincingly** show that one such putative pseudokinase, the immune receptor EFR achieves an active conformation following phosphorylation by a co-receptor kinase, and then in turn activates the co-receptor kinase allosterically to enable it to phosphorylate down-stream signaling components. This manuscript will be of interest to scientists focusing on cell signalling and allosteric regulation.

Introduction

Plants and metazoans respond to extracellular signals through different sets of plasma membrane receptors. Whereas the G-protein coupled receptor family expanded in metazoans, the receptor kinase (RK) and receptor protein (RP) families expanded in plants (Shiu and Bleecker, 2003 [↗](#), 2001 [↗](#); Trusov and Botella, 2016 [↗](#)). Plant RKs resemble metazoan receptor tyrosine kinases (RTKs) in their organization, containing an extracellular ligand-sensing domain that is coupled to an intracellular kinase domain by a single-pass transmembrane helix (Hohmann et al., 2017 [↗](#); Lemmon and Schlessinger, 2010 [↗](#)). In contrast to RTKs, however, the intracellular kinase domain of plant RKs is a serine/threonine kinase domain most closely related to interleukin-1 receptor associated kinases (IRAKs)/Pelle kinases (Shiu and Bleecker, 2003 [↗](#), 2001 [↗](#)) – although dual-specificity kinase activity has been reported in some cases (Liu et al., 2018 [↗](#); Luo et al., 2020 [↗](#); Macho et al., 2014 [↗](#); Oh et al., 2009 [↗](#); Perraki et al., 2018 [↗](#)).

The leucine-rich repeat (LRR)-RKs are the most extensively studied sub-family of *Arabidopsis thaliana* (hereafter *Arabidopsis*) RKs. They primarily sense peptide ligands that regulate growth and development, or molecular patterns that are released during damage or microbial infection (Couto and Zipfel, 2016 [↗](#)). Ligand-binding LRR-RKs have long ectodomains (>20 LRRs), and recruit short LRR ectodomain-containing co-receptor kinases (coRKs) upon ligand perception (Bender and Zipfel, 2023 [↗](#); Hohmann et al., 2017 [↗](#)), most of which belong to the SERK (SOMATIC EMBRYOGENESIS RECEPTOR KINASE) family. One of the most well characterized LRR-RKs is BRI1 (BRASSINOSTEROID INSENSITIVE 1), which recruits the coRKs SERK1 and SERK3/BAK1 (BRI1-ASSOCIATED KINASE 1) upon brassinosteroid (BR) perception (Albrecht et al., 2008 [↗](#); He et al., 2000 [↗](#); Hothorn et al., 2011 [↗](#); Nam and Li, 2002 [↗](#); Santiago et al., 2013 [↗](#)). After ligand perception, the intracellular kinase domains of BRI1 and BAK1 reciprocally trans-phosphorylate each other in their activation loops (Hohmann et al., 2017 [↗](#)), and BAK1 then phosphorylates BRI1 in its juxtamembrane segment and C-tail to propagate BR signaling (Wang et al., 2008 [↗](#), 2005 [↗](#)). BRI1 exemplifies a set of BAK1-dependent LRR-RKs that have RD-type intracellular kinase domains and require their catalytic activity to signal (Cao et al., 2013 [↗](#); Kosentka et al., 2017 [↗](#); Taylor et al., 2016 [↗](#)). Other LRR-RKs such as EFR (ELONGATION FACTOR TU RECEPTOR) instead have non-RD intracellular kinases, and are thought not to *trans*-phosphorylate their associated coRK following ligand perception (Schwessinger et al., 2011 [↗](#)). Moreover, kinase inactive mutants of EFR (D849N or K851E) retain signaling function, a result that challenges the generality of the reciprocal trans-phosphorylation model (Bender et al., 2021 [↗](#)).

EFR perceives the pathogen-associated molecular pattern (PAMP) ELONGATION FACTOR TU, or its active peptide epitope elf18 (Zipfel et al., 2006 [↗](#)). PAMP perception triggers heterodimerization with the coRK BAK1, resulting in phosphorylation of the EFR intracellular kinase domain (Bender et al., 2021 [↗](#); Roux et al., 2011 [↗](#); Schulze et al., 2010 [↗](#); Schwessinger et al., 2011 [↗](#)). The signal is subsequently relayed to the cytoplasmic kinases BIK1 (BOTRYTIS-INDUCED KINASE 1) and PBL1 (PBS1-LIKE 1) (Li et al., 2014 [↗](#); Lu et al., 2010 [↗](#); Ranf et al., 2014 [↗](#)). The resulting Immune signaling activation elicits a battery of cellular responses, including an apoplastic oxidative burst (hereafter oxidative burst), Ca²⁺-influx, callose deposition, MAPK (MITOGEN ACTIVATED PROTEIN KINASE) activation, and transcriptional reprogramming (DeFalco and Zipfel, 2021 [↗](#)).

Initial studies *in vitro* identified phosphorylation sites in EFR that result either from auto-phosphorylation or from trans-phosphorylation by BAK1 (Wang et al., 2014 [↗](#)). More recently, *in vivo* phosphorylation sites on EFR were identified by immunoprecipitating EFR-GFP from elf18-treated seedlings (Bender et al., 2021 [↗](#)). One was a serine (S888) in the activation loop (A-loop), at which phosphorylation was consistently observed *in vitro* and *in vivo* (Bender et al., 2021 [↗](#); Wang et al., 2014 [↗](#)). Despite the non-RD nature of EFR, and its ability to signal independently of catalytic activity, ligand-inducible phosphorylation in the A-loop (S887/S888) surprisingly proved

indispensable for signaling (Bender et al., 2021 [↗](#)). Furthermore, a functionally important tyrosine in EFR (Y836) – conserved in subdomain VIa of many eukaryotic protein kinases (Lai et al., 2016 [↗](#); Luo et al., 2020 [↗](#); Perraki et al., 2018 [↗](#)) – was found to be phosphorylated after ligand treatment *in vivo* (Macho et al., 2014 [↗](#)). A phospho-ablative Y836F mutation in EFR blocks immune signaling and resistance against the phytopathogenic bacterium *Pseudomonas syringae* (Macho et al., 2014 [↗](#)). Thus, although EFR function does not require its catalytic activity, both A-loop phosphorylation and phosphorylation of the VIa subdomain tyrosine (VIa-Tyr) appear to be crucial. The mechanistic importance of these phosphorylation events remains poorly understood, but we hypothesized that they switch the EFR kinase domain into an active-like conformation that allosterically activates BAK1 in the EFR-BAK1 complex through a mechanism similar to that described for pseudokinases (Mace and Murphy, 2021 [↗](#); Sheetz and Lemmon, 2022 [↗](#)) – ultimately promoting BAK1's activity towards its substrate BIK1.

Here, we tested the hypothesis that EFR is an allosteric regulator of BAK1 using a range of different approaches. Our *in vitro* studies revealed that forcing dimerization of the EFR and BAK1 intracellular domains allosterically enhances BAK1 activity. Using a homology-guided approach, we designed mutations to stabilize the active-like conformation of the EFR kinase domain and found that they restore functionality of EFR variants that cannot be phosphorylated in the A-loop (EFR^{SSAA}) or at Y836 (EFR^{Y836F}). We also used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to analyze conformational dynamics, revealing that the Y836F mutation hampers the ability of the EFR kinase domain to adopt an active-like conformation. Collectively, our findings argue that the active conformation of the EFR kinase domain is required for allosteric activation of the BAK1 kinase domain. Finally, we present evidence suggesting that EFR activates BAK1 allosterically by supporting α C-helix positioning in BAK1.

Results

The EFR intracellular domain allosterically activates BAK1 *in vitro*

To test the hypothesis that EFR enhances BAK1 catalytic activity allosterically, we used rapamycin (Rap)-induced dimerization (RiD) to induce a complex between the isolated EFR and BAK1 intracellular domains (Banaszynski et al., 2005 [↗](#); Kim et al., 2021 [↗](#)). The RiD system was previously applied *in planta*, maintaining membrane-association by N-terminal myristoylation (Kim et al., 2021 [↗](#)). For our *in vitro* experiments, the myristoylation sites were excluded to facilitate the purification of recombinant protein. We tested two LRR-RKs: EFR and BRI1, fusing GFP C-terminally and FKBP (FK506 binding protein) N-terminally to their intracellular domains. BAK1 instead was N-terminally tagged with FRB (FKBP-Rap-binding). We first confirmed that adding Rap induced formation of FKBP-EFR/FRB-BAK1 dimers in size exclusion chromatography experiments (Figure 1A [↗](#)). We then assessed the effect of inducing RK/coRK kinase complex formation on their ability to phosphorylate BIK1^{D202N}. BIK1 was chosen as it is a reported substrate of both, EFR/BAK1 and BRI1/BAK1 complexes (Lin et al., 2013 [↗](#)). Rap addition increased BIK1^{D202N} phosphorylation when the BRI1 or EFR kinase domains were dimerized with BAK1 (Figure 1B,C [↗](#)). Kinase-dead variants with the catalytic residue (HRD-aspartate) replaced by asparagine (EFR^{D849N} and BRI1^{D1009N}), had distinct effects. BRI1^{D1009N} failed to enhance BIK1 phosphorylation substantially, whereas EFR^{D849N} retained some ability to do so (Figure 1B,C [↗](#)). The same trend was observed for phosphorylation of the BAK1 kinase domain itself, indicating that EFR also enhances BAK1 autophosphorylation activity (Figure 1B,C [↗](#)).

The increased BIK1 trans-phosphorylation observed in these *in vitro* RiD experiments could arise either from direct enhancement of BAK1 activity by the RK kinase domain or from more efficient BIK1^{D202N} recruitment to the dimerized RK/coRK complex. We found that BIK1^{D202N} did not co-elute with the EFR-BAK1 complex in size exclusion studies, indicating that stable EFR/BAK1/BIK1 trimers do not form *in vitro* (Figure 1A [↗](#)). Our findings therefore support the hypothesis that EFR




Figure 1

EFR facilitates BIK1 trans-phosphorylation by BAK1 non-catalytically.

The kinase domains of coRK BAK1 and the RKs BRI1 and EFR were tagged with RiD domains and purified from *E. coli* λ PP cells. A) Recombinantly expressed RiD-tagged kinase domains were mixed together at equimolar ratios (2 μ M), with or without addition of 10 μ M Rap as well as 10 mM $MgCl_2$ and 1 mM AMP-PNP. B) RK and coRK were mixed at an equimolar ratio at 50 nM, kinase-dead BIK1^{D202N} substrate was added at 500 nM. Reactions were carried out at RT for 10 min with 0.5 μ Ci [γ -³²P]ATP, 100 μ M ATP and 2.5 mM each of $MgCl_2$ and $MnCl_2$. Addition of 1 μ M Rap enhanced transphosphorylation of BIK1 by EFR and BRI1. Kinase-dead BRI1 failed to enhance BIK1 transphosphorylation, but kinase-dead EFR retained some ability to do so. A similar trend was observed for (auto)phosphorylation of BAK1 itself. C) Quantification of band intensities over three independent experiments of which a representative is shown in B.

increases BIK1 phosphorylation by allosterically activating the BAK1 kinase domain. Although EFR's catalytic activity is dispensable for this effect – and for immune signaling – EFR must be phosphorylated at S887/S888 in the A-loop and Y836 to signal *in vivo* (Bender et al., 2021 [↗](#); Macho et al., 2014 [↗](#)). The phospho-ablative EFR A-loop mutant EFR^{SSAA} fails to activate the RK/coRK complex, as ligand-induced phosphorylation of BAK1 S612 – a mark for active BAK1-containing receptor complexes (Perraki et al., 2018 [↗](#)) – is obstructed despite retaining the ability to associate with BAK1 in a ligand-dependent manner (Bender et al., 2021 [↗](#)). To test whether the requirement for Y836 phosphorylation is similar, we immunoprecipitated EFR-GFP and EFR^{Y836F}-GFP from mock- or elf18-treated seedlings and probed co-immunoprecipitated BAK1 for S612 phosphorylation. EFR^{Y836F} also obstructed the induction of BAK1 S612 phosphorylation (**Figure 1 – Supplement 1** [↗](#)), indicating that EFR^{Y836F} and EFR^{SSAA} impair receptor complex activation.

EFR VIa-Tyr mutation affects dynamics of regulatory kinase subdomains

Y836 in EFR corresponds in sequence and structural alignments with Y156 in the canonical kinase PKA (protein kinase A) (**Figure 2 – Supplement 1** [↗](#), **2A** [↗](#)), which is conserved in many protein kinases. We therefore speculated that Y836 may function as a pivot for key movements of the regulatory α C-helix, controlling conformational toggling of inactive/active transitions as described for its PKA counterpart (Tsigelny et al., 1999 [↗](#)). To test whether an EFR Y836F mutation in EFR interferes with assembly of the active-like EFR kinase conformation we used HDX-MS. Plotting differential HDX ($\Delta\%$ EX) between unphosphorylated EFR and EFR^{Y836F} (aa684-1031) identifies one region that is stabilized in EFR^{Y836F} compared to wild-type and two that are destabilized (**Figure 2A,B** [↗](#)). The region stabilized in EFR^{Y836F} contains the N-terminal part of the A-loop, implying that this region makes more extensive contacts with the kinase core than in the unphosphorylated wild-type kinase domain. Alternatively, the decreased deuterium uptake in the EFR^{Y836F} A-loop could arise from stabilization of a short A-loop α -helix, as seen in the inactive conformation of many kinases (such as in epidermal growth factor receptor). The two regions that become more structurally flexible in EFR^{Y836F} include the β 3- α C loop and the catalytic loop plus C-terminal end of the α E-helix – where Y836 is located (**Figure 2A,B** [↗](#)). Because these two regions are both important for conformational switching, the HDX-MS results suggest that Y836 is important in regulating kinase domain allosteric transitions. Consistent with this, crystal structures as well as AlphaFold2 models of active kinase conformations (Faезov and Dunbrack, 2023 [↗](#)) suggest that the side-chain of this tyrosine forms hydrogen-bonds (H-bond) with the α C- β 4 loop backbone to establish an inter-lobe connection (**Figure 2 – Supplement 1** [↗](#)). Loss of this inter-lobe connection may underlie the observed alterations in EFR^{Y836F} conformational dynamics in EFR^{Y836F}, resulting from inaccessibility of the active-like conformation.

Kinase activating mutations restore partial function of EFR^{Y836F} and EFR^{SSAA}

To build on these results, we next sought to rescue stability of the active-like EFR kinase domain conformation by introducing activating mutations into EFR^{Y836F}. Kinase activating mutations are well known in human disease, and cause different malignancies (Foster et al., 2016 [↗](#); Hu et al., 2015 [↗](#)). Because the HDX-MS data indicated a destabilized α C-helix, we were specifically interested in activating mutations thought to stabilize the kinase α C-helix in a ‘swung-in’ state, with the goal of making homologous changes in EFR. Such mutations were systematically identified in BRAF/CRAF by searching oncogenes using phenylalanine substitutions (Hu et al., 2015 [↗](#)). We exploited these oncogenic BRAF mutations for homology-based design of putative activating EFR mutations at corresponding positions that could function as intragenic suppressors of EFR^{Y836F} (**Table 1** [↗](#) and **Figure 2 – Supplement 2A,B** [↗](#)). Since EFR already carries a phenylalanine at the position corresponding to L505 in BRAF, we generated EFR^{F761[H/M]} to resemble mutations known to potently activate BRAF (Hu et al., 2015 [↗](#)).




Figure 2

EFR^{Y836F} and EFR^{SSAA} impair the active kinase conformation, which is required for signaling function.

A) (left) HDX-MS results for unphosphorylated EFR and EFR^{Y836F} protein. The difference in percent H/D exchange in wild type EFR and EFR^{Y836F} is expressed as the $\Delta\%EX$ (wild type EFR - EFR^{Y836F}), with the positive and negative $\Delta\%EX$ indicating more stabilized and destabilized regions in EFR^{Y836F}, respectively, compared to wild-type EFR. The $\Delta\%EX$ values at different labeling time points are shown as colored lines, as indicated in the figure. The horizontal dotted black lines indicate the 98% confidence interval for the $\Delta\%EX$ data ($\pm 7.18\%$, corresponding to ± 0.4 Da difference between wild type and Y836F percent exchange) calculated as described previously (Houde et al., 2011). Regions with $\Delta\%EX$ values that exceed this confidence limit are indicated as colored bars in the figure, including the $\beta 3$ - αC loop (orange), the catalytic loop plus part of αE (purple), and the A-loop (blue). These regions are colored in the AlphaFold2-derived model of the EFR kinase domain shown at right, in which Y836 is shown as a purple sphere. All data are the average of three independent biological repeats ($n=3$) with three technical repeat experiments each. A summary of the HDX-MS analysis is presented in **Table 2**. B) HDX-MS analysis of representative peptides from regions with significantly different HD exchange. Frames are color-coded according to regions in A. Amino acid range of the peptides in full length EFR are indicated in the top left corner and the sequence below. C,D) Secondary site mutation EFR F761[H/M] partially restores function of EFR^{Y836F} (C) and EFR^{SSAA} (D). Full length EFR and its variants were expressed transiently in *N. benthamiana* and their function was tested in an oxidative burst assay. EFR F761H partially restored oxidative bursts of EFR^{Y836F} and EFR^{SSAA}. Outliers are indicated by asterisk in addition to the outlier itself and are included in statistical analysis; Statistical test: Kruskal-Wallis test ($p < 2.2 \times 10^{-16}$ in C, $p = 1.163 \times 10^{-7}$ in D), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$) Groups with like lowercase letter designations are not statistically different.

EFR mutation	Analogous oncogenic mutation	Mode of action	Source
L743F	BRAF L485F	Extended hydrophobic interaction network along the α C-helix	Hu et al., 2015
F761[H/M]	BRAF L505[F/H/M]	Enforcement of hydrophobic interactions in the regulatory spine	Hu et al., 2015
Δ NLLKH	BRAF Δ NVTAP	Shortening of β 3- α C-helix loop, pulling 'in' the α C-helix	Foster et al., 2016
L873E	BRAF V600E	Upward bending of C-terminal α C-helix end	Hu et al., 2015

Table 1

Homology-based design of putative intragenic suppressor mutations for EFR.

The list contains the residue number of EFR and the analogous oncogenic mutation in BRAF, as well as a short description of the mode of action of the oncogenic mutation. See **Figure 2 – Supplement 1B** [for structural locations](#).

Data Set	Wild-type EFR	EFR^{Y836F}
HDX reaction details	20 mM HEPES, 100 mM NaCl, pD 7.4	20 mM HEPES, 100 mM NaCl, pD 7.4
HDX time course	0, 10, 60, 600, 3600, and 7200 sec	0, 10, 60, 600, 3600, and 7200 sec
HDX control samples	8 M urea-D4 for fully deuterated standard	8 M urea-D4 for fully deuterated standard
Back-exchange	46%	49%
# of Peptides	143	153
Sequence coverage	100%	100%
Ave peptide length / Redundancy	12.7/5.44	13.3/6.06
Replicates	n = 3 biological repeats (3 technical/n)	n = 3 biological repeats (3 technical/n)
Repeatability (Ave SD)	0.129 Da (2.28 %)	0.111 Da (2.09 %)
Significant differences in HDX (98% CL)	0.395 Da (7.18 %)	

Table 2

Summary table of HDX-MS analysis

The putative activating mutations were introduced into either EFR^{WT} or EFR^{Y836F} and transiently expressed in *Nicotiana benthamiana* to test receptor function. As expected, heterologous expression of EFR^{WT} but not of EFR^{Y836F} conferred elf18 sensitivity (**Figure 2B** [↗](#), **Figure 2 – Supplement 2C** [↗](#)). When introduced on their own into EFR^{WT}, the single mutations L743F, F761[H/M], and L873E were all consistent with wild-type EFR function, supporting an elf18-induced oxidative burst, except for the Δ NLLKH deletion (**Figure 2 – Supplement 2C** [↗](#)). Intriguingly, the F761[H/M] mutations were also able to partially restore the ability of EFR^{Y836F} to support an elf18-induced oxidative burst (**Figure 2B** [↗](#) and **Figure 2 – Supplement 2C** [↗](#)). This observation also extended to EFR^{SSAA} (**Figure 2C** [↗](#)), arguing that the F761[H/M] mutations, that stabilizes the regulatory spine, support the ability of EFR to trans-activate BAK1.

EFR A-loop phosphorylation was reported previously to be indispensable for EFR function, and led to the hypothesis that it controls conformational switching, despite EFR being a non-RD kinase (Bender et al., 2021 [↗](#)). Our finding that the F761H mutation restores EFR^{SSAA} function further supports this hypothesis. Nevertheless, how EFR A-loop phosphorylation facilitates conformational switching is unclear. In our AlphaFold2 models of the EFR kinase domain, we noted that two basic residues from the β 3- α C loop and the α C-helix extend towards the A-loop and, similar to PKA H87 (Meharena et al., 2016 [↗](#)), may coordinate A-loop phosphorylation (**Figure 2 – Supplement 3** [↗](#)).

EFR F761H restores function of EFR^{Y836F} and EFR^{SSAA} in Arabidopsis

We next generated stable Arabidopsis complementation lines expressing *pEFR::EFR(variant)-GFP::HSP18t* constructs in the null *efr-1* background. Because the F761H mutation showed greater ability than F761M to rescue function of both EFR^{Y836F} and EFR^{SSAA} (**Figure 2B,C** [↗](#)), we chose this secondary mutation for the generation of complementation lines. Two independent homozygous complementation lines were isolated, with similar accumulation of EFR-GFP protein in the T3 generation. For EFR^{F761H/Y836F}, only one homozygous T3 line could be isolated, so a heterozygous T2 line with two T-DNA insertion events was used for physiological experiments. Similar to experiments in *N. benthamiana*, the oxidative burst was partially restored in stable Arabidopsis complementation lines that express EFR^{F761H/Y836F} or EFR^{F761H/SSAA} (**Figure 3 – Supplement 1A** [↗](#)).

The oxidative burst is only one of multiple cellular responses triggered by elf18. We therefore also tested whether other immune signaling responses are restored in the EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines. Consistent with previous results, EFR^{Y836F} and EFR^{SSAA} lines were both less sensitive to treatment with 5 nM elf18 than those with wild-type EFR in seedling growth inhibition (SGI) assays (Bender et al., 2021 [↗](#); Macho et al., 2014 [↗](#)) (**Figure 3 – Supplement 1B** [↗](#)). As expected, both independent complementation lines of EFR^{F761H/Y836F} and EFR^{F761H/SSAA} exhibited enhanced SGI compared to EFR^{Y836F} and EFR^{SSAA}, respectively (**Figure 3 – Supplement 1B** [↗](#)). We also observed that MAPK activation was abolished or severely impaired in both EFR^{Y836F} and EFR^{SSAA} complementation lines (**Figure 3 – Supplement 1C** [↗](#)) and recovered in EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines (**Figure 3 – Supplement 1C** [↗](#)).

The recovery of multiple immune responses in EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines suggested that they retain fully functional elf18 signaling and that effective resistance against bacteria can be established. To confirm this, we tested the transgenic lines for resistance against *Agrobacterium tumefaciens*. Infection by this bacterium is restricted in Arabidopsis by EFR, so loss-of-function mutants like *efr-1* are more susceptible (Zipfel et al., 2006 [↗](#)). *A. tumefaciens* carrying a plasmid with an intronic version of the β -glucuronidase (GUS) gene was used to evaluate infection success. GUS activity in plant protein extracts following infection correlates with the ability of the bacteria to transiently transform plant cells. Significant GUS activity was detected in *efr-1* (**Figure 3A** [↗](#)), consistent with successful *A. tumefaciens* infection, but only little was seen in wild-type EFR complementation lines, reflecting resistance to infection (Bender et al., 2021 [↗](#); Zipfel et al., 2006 [↗](#)). The EFR^{Y836F} and EFR^{SSAA} complementation




Figure 3

EFR^{F761H/Y836F} and EFR^{F761H/SSAA} recover receptor complex activation.

A) In infection assays, GUS activity was high in the positive control *efr-1* line. GUS activity level was reduced in the EFR^{WT} and EFR^{F761H} complementation lines, but much less so in the EFR^{Y836F} and EFR^{SSAA} complementation lines. By contrast, EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines displayed substantially repressed GUS activity. Each experiment was repeated three times with similar results. Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p = 5.704 \times 10^{-7}$), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$). Groups with like lowercase letter designations are not statistically different. B) In IP kinase assays, ligand-induced interaction of EFR^{WT} and EFR^{F761H} with BAK1 increased transphosphorylation of BIK1^{D202N}, but this was abolished for EFR^{Y836F} and EFR^{SSAA}. Both EFR^{F761H/Y836F} and EFR^{F761H/SSAA} showed partially restored BIK1^{D202N} trans-phosphorylation as well as BAK1 S612 phosphorylation (across four replicates for EFR^{F761H/SSAA} and in two out of four replicates for EFR^{F761H/Y836F}). Samples were also probed for MAPK phosphorylation for effective ligand treatment. Treatment: 100 nM elf18 for 10 min. C) Quantification of BIK1^{D202N} band intensity observed in autoradiographs from the four independent replicates performed. Dotted red line indicates unchanged band intensity in mock vs. elf18 treatment.

lines were both more susceptible to *A. tumefaciens* transformation than wild-type EFR complementation lines, as indicated by elevated GUS activity (**Figure 3A**), but this was greatly diminished in the EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines. Hence, these experiments show that the EFR F761H mutation restores full signaling function of EFR^{Y836F} and EFR^{SSAA} and thus resistance against *A. tumefaciens*.

EFR^{F761H/Y836F} and EFR^{F761H/SSAA} restore BIK1 trans-phosphorylation

As shown **Figure 3** and **Figure 1 – Supplement 1**, EFR^{Y836F} and EFR^{SSAA} are impaired in elf18-triggered immune signaling at the level of receptor complex activation. In both cases BAK1 S612 phosphorylation is reduced, resulting in compromised ability to *trans*-phosphorylate BIK1. We therefore asked next whether EFR^{F761H/Y836F} and EFR^{F761H/SSAA} show restored ability to induce BAK1 autophosphorylation and resulting BIK1 trans-phosphorylation. We performed semi-*in vivo* IP-kinase assays in which EFR-GFP variants were immunoprecipitated from two-week-old seedlings after 10 min mock or 100 nM elf18 treatment, and kinase activity of the complex was assessed by monitoring phosphorylation of recombinant His-BIK1^{D202N} substrate. The EFR^{WT}-GFP-BAK1 complex showed pronounced BIK1 phosphorylation compared with the unliganded control (**Figure 3B, C**). In contrast, although BAK1 co-precipitated with both EFR^{Y836F}-GFP and EFR^{SSAA}-GFP after elf18 treatment, these complexes failed to increase BIK1^{D202N} trans-phosphorylation compared with the unliganded controls. They also showed reduced levels of BAK1 phosphorylation at S612 (**Figure 3B,C**). However, BAK1 S612 phosphorylation (for EFR^{F761H/Y836F} in two out of four experiments) and BIK1^{D202N} trans-phosphorylation were partially restored for EFR^{F761H/Y836F} and EFR^{F761H/SSAA} in this assay (**Figure 3B,C**), arguing that the functional rescue observed *in vivo* reflects BAK1 activation effects.

Towards a mechanistic understanding of BAK1 allosteric activation by EFR

A phospho-ablative mutation of the BAK1 VIa-Tyr (Y403F) – analogous to Y836F in EFR – has also been reported to compromise elf18-induced signaling by interfering with receptor complex activation (Perraki et al., 2018). We recapitulated this finding using only the intracellular domains of EFR and BAK1, fusing them to FKBP and FRB domains with myristoylation sequences and inducing dimerization with Rap in *N. benthamiana* (**Figure 4** and **Figure 4 – Supplement 1A**). This approach allowed us to investigate BAK1 variants without interference of endogenous NbSERKs. We wondered whether BAK1^{Y403F} could be rescued by introducing a mutation into its regulatory spine that stabilizes the active-like conformation, as seen for F761[H/M] in EFR. Indeed, introducing the analogous mutation (I338H) into BAK1 partly restored the oxidative burst for BAK1^{I338H/Y403F} when dimerized with EFR^{WT} (**Figure 4 – Supplement 1A**), suggesting that BAK1^{Y403F} is perturbed, like EFR^{Y836F}, in accessing its active conformation. Analogies with allosteric regulation of other kinases and pseudokinases (Hu et al., 2013; Mace and Murphy, 2021; Sheetz and Lemmon, 2022; Zhang et al., 2006) led us hypothesize that EFR might stabilize the active-like conformation of BAK1 intermolecularly – helping to position the BAK1 α C-helix (in the EFR-BAK1 complex) to activate immune signaling. If this is correct, EFR that is partly ‘locked’ in its active-like conformation may be able to rescue (in *trans*) the function of a signaling-inactive BAK1 mutant with a destabilized α C-helix (as in BAK1^{Y403F}). We therefore asked whether EFR^{F761H} could achieve this, since it exhibited the tendency for increased BIK1^{D202N} trans-phosphorylation in IP-kinase assays (**Figure 3B,C**) and for an accelerated oxidative burst in *N. benthamiana* (**Figure 4 – Supplement 2A,B**). Intriguingly, when EFR^{F761H} was paired with BAK1^{Y403F}, the Rap-induced oxidative burst was partially restored (**Figure 4**), suggesting that EFR^{F761H} can partially restore BAK1^{Y403F} function. The fact that no oxidative burst was seen when EFR^{F761H} was paired with catalytically inactive BAK1^{D416N} suggests that this restoration does not occur through a direct catalytic mechanism mediated by EFR^{F761H} (**Figure 4 – Supplement 2C**), supporting the hypothesis of allosteric regulation.




Figure 4

EFR^{F761H} recovers BAK1^{Y403F} function.

The cytoplasmic domains of BAK1 and EFR variants with fused RiD-tags were transiently expressed in *N. benthamiana* and leaf discs were treated with Rap to induce dimerization. EFR and EFR^{F761H} induced a similar total oxidative burst when BAK1 was co-expressed. The co-expression of BAK1^{Y403F} and EFR diminished the oxidative burst, which was restored partially when EFR^{F761H} was co-expressed. Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p < 8.516 \times 10^{-7}$), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$) Groups with like letter designations are not statistically different.

Catalytic independence is only observed for Arabidopsis sp. LRR-RK XIIa kinase domains

EFR belongs to LRR-RK subfamily XIIa (Figure 5A), of which two other RKs are functionally described immune RKs in Arabidopsis: FLS2 and XPS1 (XANTHINE/URACIL PERMEASE SENSING 1) (Gómez-Gómez and Boller, 2000; Mott et al., 2016). This subfamily has been implicated more generally in immune signaling, which is supported by induction of immune signaling of *in vivo* dimerized FLS2, EFR, or XPS1-LIKE 1 (FEXL1) intracellular domains with BAK1 (Kim et al., 2021). However, the ligands are not known for most subfamily-XIIa RKs (Dufayard et al., 2017; Kim et al., 2021). Because EFR does not require its catalytic activity, we wondered whether other LRR-RK XIIa kinase domains similarly function non-catalytically, in a manner similar to pseudokinases. To test this hypothesis, we fused the EFR ectodomain to the transmembrane helix and intracellular domain of different LRR-RK XIIa members to generate elf18 responsive RKs that can dimerize with BAK1/SERKs (Rhodes et al., 2021). These chimeric proteins were expressed transiently in *N. benthamiana* leaves, and their immune signaling function was tested by elf18 treatment in oxidative burst assays. All chimeras induced an oxidative burst (Figure 5B), except XIIa2 (the closest FLS2-related kinase), which exhibited only a very minor response. To determine whether their signaling function required kinase activity, we next tested variants with mutations in the catalytic site (replacing the putative catalytic base HRD-aspartate with asparagine). EFR^{D849N} induced a robust oxidative burst as expected as well as FEXL1^{D838N} and the closely related XIIa5^{D839N} (AT3G47570). Similarly, XPS1^{D856N} and XIIa6^{D840N} (AT3G47090) induced an oxidative burst independently of their catalytic activity, but the total oxidative burst was reduced compared to the catalytically active variants. Protein levels of catalytic site mutants accumulated comparably to their corresponding wild-type versions (Figure 5 – Supplement 2). In contrast, the catalytically inactive FLS2^{D997N} showed a diminished oxidative burst (Figure 5B), suggesting that it may be mechanistically distinct. Furthermore, kinetic differences for the oxidative burst of Arabidopsis XIIa kinase domains were observed. XPS1^{D856N} and XIIa6^{D840N} showed a delayed oxidative burst (Figure 5 – Supplement 1A,B). Also, EFR^{D849N} exhibited a delay of approximately five to seven minutes compared to wild-type EFR. In contrast, oxidative bursts induced by FEXL1^{D838N} and XIIa5^{D839N} were only slightly delayed compared to their corresponding catalytically active kinase domains. We corroborated these findings for XIIa5 by performing *in vitro* kinase assays, observing that BIK1^{D202N} and BAK1 phosphorylation increased after Rap application as effectively for XIIa5^{D839N} as for wild-type XIIa5 (Figure 5 – Supplement 1C,D). Taken together, our results imply that catalytic activity for XIIa5 is almost fully dispensable.

Because most Arabidopsis LRR-RK XIIa kinase domains execute their signaling function at least to some extent independently of their catalytic activity, we went on to test XIIa kinase domains from other species, that we selected from a phylogenetic tree of LRR-RK XIIa kinases built from previous phylogenetic analysis (Figure 5A, Dufayard et al., 2017). The selected catalytically active XIIa kinase domains from *Oryza sativa* (XA21), *Populus trichocarpa* (PtXIIa), *Solanum lycopersicum* (SlXIIa), *Glycine max* (GmXIIa), *Brassica rapa* (BrEFR), and *Arabidopsis lyrata* (AlEFR), induced an oxidative burst (Figure 5C; Figure 5 – Supplement 1A,B). However, catalytic site mutants of all non-Arabidopsis XIIa RKs accumulated similar to their wild-type counterparts and abolished their function in oxidative burst assays (Figure 5C Figure 5 – Supplement 2).

Discussion

Our study provides insights into the non-catalytic activation mechanisms of the EFR-BAK1 complex. Rather than requiring its kinase activity to transactivate BAK1, our results suggest that the EFR kinase domain undergoes a ‘conformational toggle’ to an active-like state that permits




Figure 5

Related EFR kinases from LRR-RK XIIa in the Arabidopsis genus can function independent of their catalytic activity.

A) Phylogenetic analysis of LRR-RK subfamily XIIa. Selected LRR-RK XIIa kinase domains are labeled and highlighted with purple points. The EFR-like clade contains all *Arabidopsis* XIIa kinases except FLS2 and XIIa2 and also selected XIIa kinases from *Arabidopsis lyrata* and *Brassica rapa*. B,C) The ectodomain of EFR was fused to the transmembrane and intracellular domain of selected LRR-RK XIIa members to create elf18-responsive chimeras for testing the immune signaling function and catalytic dependency of the related kinase domains. The chimeras were transiently expressed in *N. benthamiana* and tested in oxidative burst assays. All Arabidopsis LRR-RK XIIa members induced an oxidative burst except XIIa2, the closest FLS2 related kinase in the subfamily. Catalytic dependency of the kinase domains appears to vary from kinase to kinase, with catalytically dead versions of EFR, FEXL1 and XIIa5 inducing a WT-like oxidative burst and XPS1 and XIIa6 displaying a reduced oxidative burst. FLS2 kinase dead exhibited a diminished oxidative burst. Experiments were repeated three times with similar results.

allosteric *trans*-activation of BAK1. EFR function is impaired by perturbation of structural elements that are important for conformational switching – specifically, mutation of the subdomain VIa Y836 or ablation of A-loop phosphorylation sites – but these effects can be reversed by intragenic suppressor mutations that stabilize the active-like conformation, notably the F761H mutation.

Non-catalytic functions of kinases and pseudokinases are human disease-relevant, and have emerged as important signaling regulators in metazoans (Mace and Murphy, 2021 [↗](#); Schmidt et al., 2021 [↗](#); Sheetz and Lemmon, 2022 [↗](#)). By comparison, very little is known about pseudokinases or non-catalytic kinase functions in plants, although pseudokinases are as prevalent in plant as in metazoan kinomes (Kwon et al., 2019 [↗](#)). Our data demonstrate that EFR and potentially other Arabidopsis XIIa kinases function as allosteric regulators of BAK1 kinase activity, implying pseudokinase-like functions. Thus, our findings establish precedence for non-catalytic mechanisms, specifically allosteric regulation, in plant RK signaling.

Phosphorylation of EFR is crucial for signaling function and potentially supports the conformational toggle. Nevertheless, our results do not resolve how phosphorylation of the A-loop or VIa-Tyr facilitate conformational toggling for EFR, and structural studies will be required to address this question. However, our HDX-MS analysis of unphosphorylated protein suggests that EFR^{Y836F} causes the active-like conformation to become inaccessible, potentially due to a lack of an inter-lobe H-bond – consistent with earlier studies describing the corresponding VIa-Tyr as a pivot for α C-helix movements in PKA (Taylor and Kornev, 2011 [↗](#); Tsigelny et al., 1999 [↗](#)). Recent analysis of the PKA hinge region demonstrate the importance of its integrity for coordinated conformational changes in the N- and C-lobe (Olivieri et al., 2023 [↗](#); Wu et al., 2023 [↗](#)). Whether EFR VIa-Tyr phosphorylation contributes to these coordinated conformational changes is unclear. We attempted to directly address the role of pY836 in EFR conformational dynamics using HDX-MS but were unable to produce sufficient recombinant protein with a pTyr-analog incorporated at the Y836 site. However, phosphorylation of the VIa-Tyr presumably distorts the hinge region due to its proximity to the α C- β 4-loop. Alternatively, the VIa-pTyr and C-terminal end of the α E-helix must rotate outwards (**Figure 2 – Supplement 1** [↗](#)). Rotation of the α E-helix, however, would have direct impact on the positioning of the catalytic loop and RS1. Of note, functional importance of VIa-Tyr phosphorylation was assigned based on correlation between its phosphorylation and functional impairment by phenylalanine substitution in multiple plant RKs (Liu et al., 2018 [↗](#); Luo et al., 2020 [↗](#); Macho et al., 2014 [↗](#); Perraki et al., 2018 [↗](#)), making it possible that functional importance of its phosphorylation confounded a structural role. Future computational protein-structure prediction techniques that consider post-translational modifications will aid in elucidating the effect of EFR VIa-Tyr phosphorylation on EFR's conformation. Nevertheless, mutation of VIa-Tyr may be a useful tool to break pseudokinase/non-catalytic functions by impeding conformational toggling in a way that is more effective than using conventional kinase-dead mutations.

Basal BAK1 activity *in vitro* is low compared to its robustly enhanced activity after Rap-induced dimerization (**Figure 1B,C** [↗](#); **Figure 5 – Supplement 1C,D** [↗](#)), which might be further reduced *in planta* by negative regulators (e.g. protein phosphatases) (Segonzac et al., 2014 [↗](#)). We propose that, by increasing the local concentration, ligand-induced association of EFR and BAK1 allows partially active BAK1 to phosphorylate the adjacent EFR A-loop. This in turn allows wild-type EFR to adopt the active-like conformation that can allosterically fully activate BAK1 to promote substrate phosphorylation. The activating mutation EFR F761H potentially circumvents the requirement of A-loop phosphorylation since it partially restored EFR^{SSAA} function. Consistently, EFR^{F761H} showed elevated BAK1 trans-phosphorylation in IP-kinase assays and an accelerated oxidative burst (**Figures 3B, C** [↗](#); **Figure 4 – Supplement 2A, B** [↗](#)), suggesting constitutive assembly of the active-like conformation. However, EFR^{F761H} still requires catalytic activity of complexed BAK1 (**Figure 4 – Supplement 1** [↗](#)).

Our data demonstrate that allosteric BAK1 kinase activation plays a key role in EFR-BAK1-mediated immune signaling. The partial recovery of BAK1^{Y403F}, which we hypothesize is impaired in α C-helix positioning, by EFR^{F761H} suggests a mechanism for allosteric regulation involving BAK1 α C-helix positioning. Indeed, multiple metazoan kinases are allosterically regulated by α C-helix positioning (Sheetz and Lemmon, 2022 [↗](#)). Moreover, BAK1 has a high propensity for a disordered α C-helix (Moffett et al., 2017 [↗](#)), suggesting its correct positioning requires additional support. Different orientations of kinase-kinase dimers, in which allosteric regulation occurs at the α C-helix, were previously described (Mace and Murphy, 2021 [↗](#); Sheetz and Lemmon, 2022 [↗](#)). Structural analysis will be required to resolve the exact interaction interface for allosteric activation in the EFR-BAK1 kinase dimer and to design interface-disrupting mutations for structure-function analysis but is beyond the scope of the present work.

Allosteric activation of BAK1/SERKs is partially preserved in Arabidopsis LRR-RK XIIa kinases (Figure 5 [↗](#)). Whether these kinases function solely non-catalytically, as suggested by XIIa5^{D839N} (Figure 5 [↗](#), Figure 5 – Supplement 1 [↗](#)), or contribute also catalytically to signaling activation is unclear since oxidative bursts induced by all functional catalytic base mutants of XIIa kinases were delayed (Figure 5 – Supplement 1A,B [↗](#)). Catalytic base mutation may affect conformational dynamics, which we show are important for EFR function (Figure 2 [↗](#)), confounding our interpretation. Inactive XIIa kinases with intact conformational dynamics may clarify the extent of catalytic contribution and could be obtained by development of selective inhibitors or engineering analog sensitive kinases. Alternatively, catalytic independency could be a recent innovation in Arabidopsis sp. XIIa kinases, that is taxonomically restricted due to a strong negative selection on the kinase domain (Man et al., 2023 [↗](#)) but further study is required to test this hypothesis.

Taken together, our results add to growing evidence that non-catalytic functions of kinases are similar to *bona fide* kinases controlled by conformational switching (Sheetz et al., 2020 [↗](#); Sheetz and Lemmon, 2022 [↗](#)) and further set precedence for discovering more non-catalytic mechanisms in plant RK signaling where pseudokinases are particularly prevalent (Kwon et al., 2019 [↗](#)).

Limitations of the study

In our *in vitro* kinase assays using the RiD system, the proteins were freely diffusing as they were produced as soluble entities. Freely diffusing components, however, do not fully resemble the *in planta* mode of activation where the plasma membrane restricts the free movement. The colocalization of RK/coRK complexes with their substrates may be a supporting component of signaling activation, which we did not capture in our *in vitro* assays.

It is yet unclear whether EFR phosphorylates BAK1 efficiently on activation-relevant residues in the context of stabilized proximity. This information will ultimately help to deduce whether the catalytic activity of EFR contributes to signaling activation and whether even marginal catalytic activity of EFR^{D849N} may be sufficient to support signaling activation.

Further, our study relies heavily on mutations. Mutations can have pleiotropic effects as they impact conformational plasticity which supports catalytic activity and non-catalytic functions. Thus, it is difficult to untangle catalytic from non-catalytic functions using solely mutations. Eventually, it would be beneficial to obtain structural information of native proteins in a complex and monitor site-specific and time-resolved phosphorylation on complex components.

We do not have experimental support for EFR^{F761H} stabilizing or facilitating the transition into an active-like conformation and relieving the negative effect of the Y836F mutation in EFR^{F761H/Y836F}. It would have been beneficial to obtain HDX-MS data for these mutants as well, but we could not produce sufficient protein to do so. Thus, we rather derived the biochemical and structural effects of the EFR^{F761H} mutant by homology to mammalian kinases, e.g. BRAF.

Acknowledgements

We thank Tamaryn Ellick for plant care, Ursin Stirnemann for help establishing the Rap-induced dimerization work, and Fabian Lachmann for help with preparative tasks. Further, we thank Jeonghayng Park, Eunkyoo Oh and Jungmook Kim for sharing materials of and information about the Rap-induced dimerization system. All past and current members of the Zipfel group are thanked for fruitful discussions.

Funding

This project was funded by the University of Zürich (C.Z.), the Swiss National Science Foundation grant no. 31003A_182625 (C.Z.), a joint European Research Area Network for Coordinating Action in Plant Sciences (ERA-CAPS) grant ('SICOPID') from UK Research and Innovation (BB/S004734/1) (C.Z.), and by NIH grant R35-GM122485 (M.A.L.).

Material and Methods

Plant material and growth conditions

For complementation experiments, the *efr-1* T-DNA insertional mutant was used (Zipfel et. al 2006). A comprehensive list of transgenic line used in this study can be found in **Table 8** [↗](#).

For sterile plant culture, the growth conditions were $120 \mu\text{mol s}^{-1} \text{m}^{-2}$ illumination during 16 h light/8 h dark cycles at a constant temperature of 22°C. Sterilization of seeds was performed by chlorine gas surface sterilization for 6 h. Sterile seeds were germinated on 0.8% (w/v) phyto agar plates containing 0.5x Murashige and Skoog (MS, Duchefa) basal salt mixture and 1% (w/v) sucrose. After 5 days of growth on agar plates, seedlings were transferred to liquid 0.5x MS medium containing 1% (w/v) sucrose in either sterile 6- (IP-kinase), 24- (MAPK activation), or 48-well (seedling growth inhibition) plates.

For plant growth on soil, seeds were resuspended in 0.05% (w/v) agarose solution and stratified for at least 16 h in the dark at 4°C. Seeds were then directly sown on soil using a Pasteur pipette.

Physiological assays

Seedling growth inhibition assay

Upon transfer to liquid culture, seedlings were exposed to either mock (no PAMP supplementation) or PAMP (5 nM elf18) treatment. After 10 days of seedling growth in liquid culture, seedlings were dry blotted on a paper towel to remove excess liquid media before measuring their fresh weight using a fine balance (Sartorius X64-S1). The relative seedling weight was calculated by dividing the seedling weight of each PAMP treated seedling by the average seedling weight of all mock-treated seedlings of the respective genotype.

MAPK activation assay

After transfer to liquid media, seedling growth continued for 10 days. The liquid medium was then decanted from the 24-well plate, and 1 ml of liquid 0.5x MS-medium containing either no elf18 supplementation (mock) or 100 nM elf18 supplementation was added to each well and seedlings

incubated for 10 min. Thirty seconds prior to the end of this incubation, seedlings were dry blotted on a paper towel, transferred to a 1.5 ml reaction tube, and flash frozen in liquid nitrogen. Frozen tissue was then stored at -80 °C.

For protein extraction, the frozen tissue was ground using a plastic pestle in the 1.5 ml microcentrifuge tube and analyzed as described.

Measurement of apoplastic oxidative burst

Four- to five-week old under a short day regime ($130 \mu\text{mol s}^{-1} \text{m}^{-2}$, 65% humidity, 10 h/14 h light/dark-cycle) soil-grown plants were used for punching out at least two leaf discs (4 mm in diameter) per plant. Leaf discs were floated on ultrapure water in a white chimney 96-well plate. The next day, the water solution was replaced with assay solution containing 100 nM elf18, 100 μM luminol and 10 $\mu\text{g/ml}$ horseradish peroxidase, immediately before recording luminescence in 1 min intervals with 250 ms integration time per well in a Tecan Spark plate reader. The luminescence recorded of all leaf discs coming from the same plant were averaged for each time point. For plotting the time course of recorded luminescence emission, the means of all plants belonging to the same genotype were averaged and the standard error of the mean was calculated, which is represented by the error bar. For calculating the time to half maximum, the timepoint of maximum oxidative burst was determined and the next 5 values included for fitting a sigmoidal curve to the oxidative burst of each leaf disc. From the fitted function, the half maximum was derived and all half maxima from leaf discs belonging to one plant were averaged.

Infection assay with GUS activity monitoring

Three to four-week-old plants were infiltrated with *A. tumefaciens* carrying pBIN19-GUS(intronic) at $\text{OD}_{600}=0.5$. *A. tumefaciens* was inoculated the day before and grown overnight. Five days after infiltration, infiltrated leaves were harvested into a 2 ml microcentrifuge tube with two $\varnothing 4$ mm glass beads and flash frozen in liquid nitrogen. Plant tissue was ground in a GenoGrinder (90 s, 1500 rpm). 600 μl of extraction buffer (50 mM $\text{NaH}_2\text{PO}_4\text{-NaOH}$, pH 7.0, 10 mM EDTA, 0.1% (v/v) Triton X-100, 0.1% (v/v) sodium lauroyl sarcosinate, 10 mM β -mercaptoethanol) was added to tissue powder and incubated for 30 min on a rotator at 4°C. Protein extracts were centrifuged (10 min, 13,000 rpm, 4°C) in a table top centrifuge, and 200 μl supernatant was collected. 100 μl of the supernatant was mixed with 100 μl extraction buffer containing 2 mM 4-methylumbelliferyl- β -D-glucopyranosid and incubated for 30 min at 37°C. 40 μl of the reaction was collected and mixed with 160 μl Na_2CO_3 to stop the reaction and enhance the fluorescence of 4-methylumbelliferone. A standard curve of 4-methylumbelliferone in extraction buffer was prepared, starting with 10 μM and using 2-fold dilution steps. Finally, fluorescence was measured in a plate reader. Protein concentration was determined using Bradford reagent with 1:20 dilution of protein extract. Fluorescence was converted into 4-MU concentration using the standard curve and 4-MU concentration was normalized to the amount of protein in the 40 μl sample divided by the incubation time.

Molecular cloning

All primers and plasmids used and generated in this study are listed in [Table 6](#) and [Table 7](#), respectively.

For recombinant expression and *in planta* complementation, the gene's cDNA sequences were subcloned from previously published cDNA clones ([Bender et al., 2021](#); [Perraki et al., 2018](#)) or synthesized with domesticated BsaI, BpiI and Esp3I sites. PCR products were inserted into level 0 Golden-Gate plasmids pICSL01005, pICH41308 ([Weber et al., 2011](#)), or the universal acceptor p641 ([Chiasson et al., 2019](#)) respectively. GoldenGate reactions were performed with 5 U of restriction enzyme and 200 U of T4 ligase in T4 ligase buffer (NEB) also containing 0.1 mg/ml BSA (NEB) ([Weber et al., 2011](#)). GoldenGate digestion ligation cycles varied between 10-20.

Site directed mutagenesis (SDM) was conducted as described (Liu and Naismith, 2008 [↗](#)) or during GoldenGate cloning by amplifying the target in two pieces that were ligated in the restriction-ligation reaction with the intended nucleotide changes in the restriction overhangs. Where SDM was performed according to Liu and Naismith, 2008 [↗](#), the PCR reaction was DpnI (New England Biolabs) digested (37°C, 1–2 h) without prior clean-ups, and then transformed into *E. coli* DH10b.

Construction of pICSL86955-35S::EFRecto-ccdB-mEGFP::HSP18t

The ccdB counter selection cassette was amplified from p641-Esp3I, and the EFR ectodomain sequence was amplified from pICSL01005-EFR using primers listed in **Table 6** [↗](#). The PCR products were purified and used together with level 0 GoldenGate plasmids for 35S promoter + TMVOmega 5'UTR, C-terminal mEGFP-tag and HSP18 terminator for assembly into pICSL86955 using BsaI (ThermoScientific) restriction enzyme and T4 DNA ligase (New England Biolabs). The GoldenGate restriction-ligation-reaction was transformed into *E. coli* One Shot™ ccdB Survival™ 2 T1R Competent Cells (ThermoFisher). Single colonies were cultured for plasmid isolation and the cloned sequence was confirmed by DNA sequencing.

Construction of p641-BsaI

Site-directed mutagenesis was performed according to Liu and Naismith, 2008 [↗](#), using primers listed in **Table 6** [↗](#) using p641-EspI as template.

Construction of pETGG

The plasmid pET28a(+)-6xHis-TEV-GB1 was linearized by PCR excluding 6xHis-TEV-GB1 sequences and the C-terminal 6xHis-tag that were replaced by the GoldenGate cloning cassette containing AATG and GCTT BsaI restriction sites, the ccdB counter selection marker, and the chloramphenicol resistance gene. The GoldenGate cloning cassette was amplified using primers listed in **Table 6** [↗](#) using p641-BsaI as template and the PCR product was ligated with the linearized pET28a(+) backbone using InFusion (Takara) cloning.

Plant transformation

Stable transformation of *Arabidopsis thaliana*

For complementation of *efr-1* T-DNA knock-out lines, the coding sequence of EFR and the mutants were cloned in the GoldenGate system as described in the section *Molecular cloning*. Sequences of final binary plasmids were confirmed by sequencing prior to transformation into *Agrobacterium tumefaciens* GV3101 by electroporation (25 µF, 200 Ω, 1.8 kV). Plants were grown to the early flowering stage and then transformed using the floral dip method with bacteria grown in YEBS medium (Clough and Bent, 1998 [↗](#); Davis et al., 2009 [↗](#)). Seeds after dip transformation were selected on 0.5x MS-agar plates containing 10 µg/ml phosphinothricin until homozygous seed batches were identified in T3 generation. These seed batches were then used for physiological assays.

Transient transformation of *Nicotiana benthamiana*

Agrobacterium tumefaciens was grown over night in liquid LB medium supplemented with kanamycin (50 µg/ml), gentamycin (25 µg/ml) and rifampicin (40 µg/ml). Cultures were diluted the next morning 1:10 in fresh LB medium (without antibiotics) and grown to an optical density OD₆₀₀ 0.8–1.2. Cultures were spun down (2,000 rcf, 10 min) and LB medium was decanted. Pellet was resuspended in infiltration medium (10 mM MES-KOH, pH 5.8, 10 mM MgCl₂), the optical density (OD₆₀₀) was determined in a spectrophotometer. For infiltration, *A. tumefaciens* carrying the construct with the gene of interest and a second strain carrying the RNA silencing suppressor p19 were mixed at a 2:1 ratio (final OD₆₀₀ = 0.5 + 0.25 = 0.75). The mixture was infiltrated into 4–5-

week-old *N. benthamiana* plants from the abaxial site of the leaf with a needle-less 1-ml syringe. Constructs within one experiment were infiltrated side-by-side into the same leaf on multiple plants. Only for testing the catalytic requirement of multiple LRR-RK XIIa kinase domains, not all constructs could be infiltrated side-by-side on one leaf.

Protein extraction from plant samples

Flash frozen tissue was ground using plastic pestles in 1.5 ml microcentrifuge tubes or, in case of coIP and IP-kinase samples, using stainless steel grinding jars and a Retsch mill (90 sec, 30 Hz). Ground tissue was mixed with extraction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1% IGEPAL detergent, 1 mM DTT, 4 mM sodium tartrate ($\text{Na}_2\text{C}_4\text{H}_4\text{O}_6$), 1% (v/v) protease inhibitor cocktail (P9599, Sigma), 1 mM PMSF, 2 mM sodium molybdate (Na_2MoO_4), 1 mM sodium fluoride (NaF), and 1 mM activated sodium orthovanadate (Na_3VO_4) at an 1:1 – 1:2 ratio (tissue powder:extraction buffer) and incubated for 30-45 min on a rotator at 4°C. For, coIP or IP-kinase assays, the samples were filtered through two layers of Miracloth into conical centrifugation tubes, which were spun at 20,000 rcf for 20 min, and supernatant was collected. Protein concentrations in the supernatants were determined using Bradford reagent. Subsequently, protein concentration was adjusted to normalize samples.

Recombinant protein expression and purification

For HDX-MS pET28a(+)-6xHis-EFR and pET28a(+)-6xHis-EFR Y836F were transformed by heat shock into BL21(DE3) pLPP (Amid Biosciences). Protein expression and purification was performed as described for proteins produced for the *in vitro* kinase assay. Conditions for growth and extraction are detailed in [Table 3](#), except, that protein was eluted from the gel filtration column in 20 mM HEPES, pH 7.2 (NaOH), 150 mM NaCl.

Unphosphorylated protein for *in vitro* RiD kinase assays were recombinantly produced in *E. coli* BL21(DE3)-V2R-pACYC LamP (Wernimont et al., 2010). From a single colony, a 10 ml lysogeny broth (LB) starter culture supplemented with 50 µg/ml kanamycin and 15 µg/ml chloramphenicol was inoculated and incubated overnight at 37°C, shaking at 220 rpm. On the next day, the starter culture was completely transferred to 1 l of LB medium containing 50 µg/ml kanamycin at 37°C with shaking to an OD_{600} of 0.6–0.8. With the addition of 300 µM isopropyl β-D-1-thiogalactopyranoside (IPTG), expression of recombinant protein was induced, and growth continued with conditions indicated in [Table 3](#). Cells were then pelleted by centrifugation at 4,000 rcf for 10 min, and pellets resuspended in protein extraction buffer (20 mM HEPES-NaOH at varying pH (see [Table 3](#)), 500 mM NaCl, 10 mM imidazole, 5% glycerol). Resuspended bacterial pellets were stored at -80°C before protein purification.

Frozen pellet suspensions were thawed in a water bath at room temperature and then transferred to ice. Cells were lysed using ultrasonication (Branson Sonifier 250) with a ø6 mm sonicator probe at 60% amplitude, with 20 s ON/40 s OFF intervals for a total of 4 cycles. Cell debris was pelleted by centrifugation at 47,850 rcf for 30 min at 4°C. The supernatant was collected and equilibrated. PureCube 100 Co-NTA agarose beads (Cube Biotech) were added for batch-binding of protein. Binding continued for 45 min while rotating at 14 rpm on a tabletop rotator at 4°C. Beads were collected by centrifugation at 500 rcf for 1 min at 4°C, and supernatant was removed using a vacuum pump. Beads were then washed twice with 10 ml ice-cold protein extraction buffer, and protein eluted in elution buffer (20 mM HEPES-NaOH, pH 8.0, 300 mM NaCl, 300 mM imidazole, 5% glycerol) by incubation for 10 min, followed by spinning down beads and collecting supernatants. Eluted protein was then filtered through a 0.22 µm spin-column filter (1 min, 4,000 rcf, 4°C) before loading onto a Superdex 200 Increase 10/300 GL (Cytiva) gel filtration column equilibrated with 20 mM HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol using an Äkta pureTM protein purification system (Cytiva). The peak fraction was collected, concentration measured by NanoDrop, and protein aliquoted and snap frozen in liquid nitrogen prior to storage at -80°C.

Protein	T after induction [°C]	t of expression [h]	pH of extraction buffer
For <i>in vitro</i> kinase assay			
EFR/EFR D849N	30	4	8.0
BAK1	30	4	8.0
BRI1/BRI1 D1009N	18	Over night	8.0
FLS2/FLS2 D997N	18	Over night	8.0
BIK1 D202N	18	Over night	7.5
For HDX-MS			
EFR/EFR Y836F	30	3	8.0

Table 3

Protein expression conditions

Hydrogen-Deuterium Exchange and Mass Spectrometry (HDX-MS)

All HDX data were collected using LEAP HDX automation (Trajan). A 5 μ L volume of freshly purified EFR^{WT} or EFR^{Y836F} at 0.3–0.6 mg/ml in 20 mM HEPES-NaOH, pH 7.2, 150 mM NaCl (5 μ L) was labeled by 20-fold dilution with 20 mM HEPES-NaOH, pH 7.4, 100 mM NaCl at 25°C. The labeled sample was quenched at different time points (10, 60, 600, 3600, and 7200 sec) by adding 100 μ L of cold 200 mM glycine buffer (pH 2.3). A fully-deuterated sample was also prepared by labeling the protein sample for 1 min with 20 mM HEPES-NaOH, pH 7.4, 100 mM NaCl, 8 M urea-d₄ (Cambridge Isotope Laboratories, Inc.). The quenched sample was immediately injected onto an Enzymate BEH pepsin column (Waters) at 2°C, and the labeled sample was digested for 3 min. The peptic peptides were trapped and separated using an Acquity UPLC BEH C18 pre-column (2.1 x 5 mm, 1.7 μ m, Waters) and Acquity UPLC BEH C18 column (1.0 x 100 mm, 1.7 μ m, Waters), respectively, using a linear gradient of 5 to 40% acetonitrile over 7 min. The MS^e data were acquired on a Synapt G2-Si (Waters) using 0.5 s scan time and ramp collision energy of 5 V to 10 V for LE and 15 V to 40 V for HE with continuous lock mass (Leu-Enk) for the mass accuracy correction.

HDX-MS Data Analysis

Peptides were sequenced using ProteinLynx Global Server 3.03 (PLGS, Waters), and the deuterium uptake of each peptic peptides was determined using DynamX 3.0 (Waters). The deuterium uptake of all analyzed peptides presented in this study is the average uptake of three biological replicates with technical triplicates per biological sample. The percent exchange of each peptic peptide (%D) was calculated by the following equation:

$$\%Ex = (m_t - m_0) / (m_f - m_0) \cdot 100$$

where m_t = the centroid mass of a peptic peptide at time, t , m_0 = the centroid mass of a peptic peptide without deuterium labeling, and m_f = the centroid mass of a peptic peptide for the fully-deuterated standard sample. The Student's t-test of the HDX data was calculated, as described previously (Houde et al., 2011 [\[link\]](#)), by using the average of standard deviations of the percent exchange data of all analyzed peptides from $n=3$ biological experiments. All data were collected and analyzed according to consensus HDX-MS guidelines (Masson et al., 2019 [\[link\]](#)). A summary of HDX-MS data is presented in **Table 2** [\[link\]](#).

In vitro kinase assay

Aliquots of purified protein stored at -80°C were thawed in a water bath at room temperature and then kept on ice. Protein concentrations were determined by measuring the absorption at 280 nm using a Nanodrop 1000 Spectrophotometer (ThermoScientific) and calculating the concentration using the computed extinction coefficient under reducing conditions (ExPASy ProtParam, **Table 4** [\[link\]](#)) of the respective protein. Kinase reactions were performed with 50 nM of each kinase in a total reaction volume of 20 μ L containing 20 mM HEPES-NaOH, pH 7.2, 2.5 mM MgCl₂, 2.5 mM MnCl₂, 1 mM DTT, 100 μ M ATP, and 0.5 μ Ci ³²P-ATP. 500 nM of 6xHis-TEV-BIK1 D202N was also added to the reaction mixture. The reaction was stopped after 10 min by adding 5 μ L 6x SDS-loading buffer (300 mM Tris, pH6.8, 30% (v/v) glycerol, 6% (w/v) SDS, 0.05% (w/v) bromophenol blue), and heating the sample at 70°C for 10 min. Subsequently, 20 μ L of the sample was loaded onto a 10% SDS-PAGE gel and protein separated by electrophoresis at 130 V for 60–70 min. Proteins were then transferred to a PVDF membrane at a current of 200 mA over 2 h. Membranes were stained the membrane with CBBG250 for 20 s and destaining (45% methanol (v/v), 10% acetic acid (v/v)) for 10 min. Finally, a phosphor-screen was exposed to the PVDF membrane overnight and imaged using an Amersham Typhoon (GE Lifesciences). Band intensities were quantified using ImageQuant software (GE Lifesciences) with background subtraction using the local median method.

Protein	Extinction coefficient (reduced state) [Abs 0.1% (=1 g/l)]	Molecular weight [kDa]
FKBP-EFR-mEGFP	7.40	80
FKBP-BRI1-mEGFP	8.26	83
FKBP-FLS2-mEGFP	6.56	79
FKBP-XIIa5-mEGFP	7.59	79.5
FRB-BAK1	15.07	55
6xHis-TEV-BIK1 ^{D202N}	9.45	47
6xHis-TEV-EFR(684-1031)	6.97	41.5

Table 4

Extinction coefficients and molecular weights retrieved from ProtParam and used for determination of protein concentration.

IP-kinase assay/co-immunoprecipitation

Forty microliters of a 50%-slurry of GFP-Trap agarose-beads (ChromoTek) per sample were equilibrated, first with 1 ml water and then twice with 1 ml extraction buffer. Beads were then prepared as a 50% slurry in extraction buffer, and 40 μ l were added to each protein extract prepared as described above. Beads were incubated with the extract for 2 h at 4°C on a rotator. Beads were then washed four times with 1 ml extraction buffer and split into halves at the last washing step. To one half, 20 μ l 2x SDS-loading buffer was added, and the sample heated for 5 min at 95°C. The other half was equilibrated with 500 μ l kinase reaction buffer (20 mM HEPES, pH 7.2, 5% glycerol, 100 mM NaCl). After pelleting the beads, the supernatant was aspirated and 20 μ l of kinase reaction buffer containing additionally 2.5 mM $MgCl_2$, 2.5 mM $MnCl_2$, 100 μ M ATP, 1 μ Ci 32 P-ATP and 0.5 μ M 6xHis-BIK1 D202N were added to each sample. Kinase reactions were incubated at 30°C for 30 min with 800 rpm shaking and were stopped by adding 5 μ l 6x SDS-loading dye and heating at 70°C for 10 min. Subsequent steps were performed as described for *in vitro* kinase assays.

SDS-PAGE and Western blotting

SDS containing gels were prepared manually. The resolving gel buffer contained 0.375 M Tris base, 0.4% SDS, pH 8.8, 10-12% acrylamide (37.5:1 acrylamide:bisacrylamide ratio), and the stacking gel buffer contained 0.125 M Tris base, 0.4% SDS, pH 6.8, 5% acrylamide (37.5:1 acrylamide:bisacrylamide ratio). Polymerization was induced by addition of 1 mg/ml ammonium persulfate and 1:2000 TEMED in case of the resolving gel or 1:1000 TEMED for the stacking gel.

Protein samples were mixed with 6x SDS loading dye (300 mM Tris, pH 6.8, 30% glycerol, 6% SDS, 0.05% bromophenol blue) and DTT was added to a final concentration of 100 mM. Samples were heated to 80-90°C for 5-10 min prior to loading the gel. Electrophoresis, with gels being submerged in SDS running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) was performed at 120-200V until the dye front reached the bottom of the gel.

Subsequently, proteins were transferred onto PVDF membranes using wet transfer. For this, the transfer stack was assembled fully submerged in transfer buffer (25 mM Tris base, 192 mM glycine, 20% MeOH). Transfer was performed at 100 V for 90 min in the cold room (4°C) with an additional ice pack in the casket. Membranes were subsequently blocked with 5% skim milk powder dissolved in Tris buffered saline containing Tween-20 (TBS-T) (20 mM Tris base, pH 7.5, 150 mM NaCl, 0.1% Tween-20) for at least 2 h. The primary antibody was then added (refer to [Table 5](#) for exact conditions) and binding allowed overnight on a shaker at 4°C. The next day, membranes were washed four times with TBS-T for 10 min each, before adding secondary antibody for at least 2 h. Membranes were then washed three times for 5 min each with TBS-T, and a fourth time with TBS.

Immunoblots were visualized using chemiluminescence. SuperSignal™ West Femto Maximum Sensitivity Substrate was prepared according to the manufacturer's manual and distributed equally over a transparent film. The membrane was rolled over the substrate to allow equal distribution of substrate on the membrane.

Structure prediction and analysis

Structures of the isolated EFR kinase domain or the intracellular domain were predicted using AlphaFold2 ([Jumper et al., 2021](#)) running it in Google CoLab ([Mirdita et al., 2022](#)). PDB files were downloaded and the best model (highest pLDDT score) was visualized in ChimeraX 1.6 ([Pettersen et al., 2021](#)). Hydrogen bonds were predicted in ChimeraX which uses angle and distance cutoffs for H-bonds described in ([Mills and Dean, 1996](#)).

Primary antibody	source	dilution	Secondary antibody	dilution
GFP-HRP	Santa Cruz Biotechnology (sc-9996)	1:1000	-	-
BAK1	(Roux et al., 2011)	1:10000	Anti-rabbit-HRP (A0545, Millipore Sigma)	1:10000
BAK1 pS612	(Perraki et al., 2018)	1:2000	Anti-rabbit-HRP (A0545, Millipore Sigma)	1:10000
FKBP12	Santa Cruz Biotechnology (sc-133067)	1:500	Anti-mouse-HRP (A0168, Millipore Sigma)	1:5000
p44/42	Cell Signaling Technology (#9101)	1:1000	Anti-rabbit-HRP (A0545, Millipore Sigma)	1:10000

Table 5

Antibodies used for immunodetection of Western blotted proteins.

Source and dilutions of antibodies are indicated.

Cloning target	Forward primer	Reverse primer
EFR	atcgGAAGACaaAATGAAGCTGTCTTTCACTTG	cgatGAAGACitCGAAccCATAGTATGCATGTCGG
EFR Y836F	ggagtTtctgcagctcatgtcatgaccctgta	gtgcagaAactccaaagctgaagccacatcat
EFR SSAA	gtttgctgctgctggtgtcagaggcacat	gcagcagcgaactggttagaagaagattctcgatcg
EFR F761H	acgatgtcgtataccctgtggtttcacattccgccata	tatggcggaaatgtgaaccaccaagggatagcacatcgt
EFR F761M	tacgatgtcgtataccctcatggtttcacattccgccata	tatggcggaaatgtgaaccaccaagggatagcacatcgt
EFR V845F	gcttaatatcacagtgagcgaaaggtcatgacaatgaacgtg	cacgttcatgtcatgacctttcgctcatgtatattaagc
EFR L743F	gctttaggaggttgaaacattacgcgcagcagagttta	taaacctcgtcgcgttaagtttcaacctcctaagc
EFR L873E	ctcagGAGctctataaatacagatcgagaatccttcta	tatagagCTCctgagccaaacaaagtcactaacatg
EFR dNLLKH	taaaagtttgggagcgacgaaagcctttagcgcggaatg	tcgtcgtcccaaaactttaaaccgacgagtttattct
EFR D849N	cactgtAatattaagccaagcaacattcttagacgat	ggcctaataT Tacagtgactcagggctcatgaca
BAK1	atcgGAAGACaaAATGGAACGAAGATTATGATCC	cgatGAAGACitAAGCcTTATCTTGGACCCGAGG
BAK1 Y403F	cttgcgtttttacatgatcattgcgacccaaga	catgtaaaaacgcgaagccctctgcagatcca
BAK1 I338H	gagatgCAtagtagcgggttcacagaactgct	ccatactaT Gcatctcaacctctgtcggaaactgc
BAK1 D416N	catcgaAatgaaagctgcaaatattttgttgatgaag	ctttcacatTtcatgaataatcttgggtgcgaatg
EFRprom	atcgGgtctctTACCGCTCTCaCTAGatcgtacgattaaagtaattgagca	atcgGgtctctCAGACGTCTCaCATTgtcgtattataaaagataaaagaaaggtt
BAK1prom	atcgGgtctctTACCGCTCTCaCTAGatcgtacgattaaagtaattgagca	atcgGgtctctCAGACGTCTCaCATTttatctcaagagattaaaaaacaac
Xlla2_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	cgatGCTCTTCICGAAccTGAACGTAGCTTCTCTGTG
Xlla3_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	cgatGCTCTTCICGAAccACGTCTGGCTGTTCTCC
Xlla4_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	cgatGCTCTTCICGAAccAGTCTCCTCGTCTCGAAA
Xlla5_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	AGATCAACTCCTTG
Xlla6_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	cgatGCTCTTCICGAAccACGTCTAGGTGTTCTCTCG
FLS2_Tmid	atcgGCTCTTCgAAGGTTCTTCTACCGGTTCTGTAT	cgatGCTCTTCICGAAccAAGTCTCGATCCTCGTTAC
AIXlla_D850N	atcgGCTCTTCAGTaATATTAAGCCAAGCAACG	atcgGCTCTTCAIACAGTGAAGTACAGGGT
BrXlla_D846N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAAC	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
GmXlla_D829N	atcgGCTCTTCAGTaATATTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTACAGGCT
PiXlla_D848N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAAC	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
SiXlla_D883N	atcgGCTCTTCAGTaATATTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
Xlla2_D803N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
Xlla3_D838N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
Xlla4_D856N	atcgGCTCTTCAGTaATATTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
Xlla5_D839N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
Xlla6_D840N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
FLS2icd_D997N	atcgGCTCTTCAGTaATCTTAAGCCAAGCAACAT	atcgGCTCTTCAIACAGTGAAGTATTTGGTCAT
FLS2_D997N	GTTCATTGTAATCTGAAGCCAGCTAATATACTCCTTGACA	CTTCAGATACAAATGAACGATGGGAAAACCATATCCAGA
EFR_ecto	atcgGGTCTCaAATGAAGCTGTCTTTTCACTTG	atcgGGTCTCacTCTTTTCAACTGACAGAGGC
EFR_Sapldo	GTATGAGGAGCTTCATAGTGCAACAAGTCGCTTC	TGAAGCTCcTATAACTTACCTTCTCATGGAACATCC
EFR_Esp3ido	TTCCCGTgTCTTTCGGGAAGCTTTTGAAGTTCG	GAAAGAcACGGGAAGTTCCTCACTCAACATATTTGTTT
ccdB cassette	atcgGGTCTCAGAAAGGGAAGAGCAAGCTGAACGAGAAACGTA	tacgGGTCTCACGAAAGAGCactggctgtgataaggga
pET28_lin	tgagatccgctgctaa	ggatatactctttaaagttaaaca
pETGG cloning cassette	AGAAGGAGATATACCAATGAGAGACCAAGCTGAA	AGCAGCCGGATCTCAAAGCAGAGACCACTGGC
P641-Bsal_mut1	agagacCaaagctgaacgagaaagctaaatgatataata	cagctttGgtctctgtagcgcctctgt
P641-Bsal_mut2	gccagtgGgtctcttctggtgtagctggg	agagacCactggctgtgataaggagcctga
6xHis-FKBP	atcgCGTCTCTACGGGTCTCaAATGggcagcagccatcatcatcatcacagcagcgccGAGTG	atcgCGTCTCTACAGAGGTCTCaACCTGAGCCGCTTTTC
6xHis-FRB	atcgCGTCTCTACGGGTCTCaAATGggcagcagccatcatcatcatcacagcagcgccATCCTC	atcgCGTCTCTACAGAGGTCTCaACCTGAGCCGCTTTT
EFR_icd (stop)	atcgCGTCTCTACGGGTCTCaAGGTaagaggaaaaagaaaaacaatgcc	atcgCGTCTCTACAGAGGTCTCaAAGCttacatagtagcatgtccgtatt
EFR_icd (no stop)	atcgCGTCTCTACGGGTCTCaAGGTaagaggaaaaagaaaaacaatgcc	atcgCGTCTCTACAGAGGTCTCaAAGCttacatagtagcatgtccgtatt
BAK1_icd (stop)	atcgCGTCTCTACGGGTCTCaAGGTgcttgggtgcgaagg	atcgCGTCTCTACAGAGGTCTCaAAGCttatcttggacccgaggg
FLS2_icd (no stop)	atcgCGTCTCTACGGGTCTCaAGGTACCTGTTGCAAGAAAAAAGAAAAAAG	atcgCGTCTCTACAGAGGTCTCaAGCAaccAACTTCTCGATCTCGTTACG
BR11_icd (no stop)	atcgGGTCTCaAGGTGGTAGAGAGATGAGGAAGAGA	atcgGGTCTCaCGAAccTAATTTTCTTCAGGAACCTCTTTATA
BR11icd_D109N	atcgGGTCTCaAaCATGAAATCCAGTAATGTGTTGC	atcgGGTCTCaAGTTCCTGTGGATGATGCGGAC

Table 6

List of primer used for molecular cloning in this study.

	Plasmid name	Source	Resistance	CZLp
Level 0 - accessories				
	p641-EFRprom(Bsal)	This paper	Gent	3900
	35S_omegaEnhancer	(Weber et al., 2011)	Spec	3719
	pICH41258-nMyr-FKBP	(Kim et al., 2021)	Spec	4861
	pICH41258-nMyr-FRB	(Kim et al., 2021)	Spec	4862
	pICSL01003-GFP	(Weber et al., 2011)	Spec	2263
	pICSL01003-mEGFP	TSL/GG suite	Spec	4772
	HSP18t	TSL/GG suite	Spec	3557
	p641-6xHis-FKBP	This paper	Gent	6501
	p641-6xHis-FRB	This paper	Gent	6502
Level 0 - genes				
	pICSL01005-EFR	This paper	Spec	6509
	pICSL01005-EFR Y836F	This paper	Spec	5654
	pICSL01005-EFR SSAA	This paper	Spec	5655
	pICSL01005-EFR F761H	This paper	Spec	5656
	pICSL01005-EFR F761M	This paper	Spec	5657
	pICSL01005-EFR dNLLKH	This paper	Spec	5660
	pICSL01005-EFR L743F	This paper	Spec	5659
	pICSL01005-EFR L873E	This paper	Spec	5668
	pICSL01005-EFR F761H Y836F	This paper	Spec	5661
	pICSL01005-EFR F761M Y836F	This paper	Spec	5663
	pICSL01005-EFR dNLLKH Y836F	This paper	Spec	5667
	pICSL01005-EFR L743F Y836F	This paper	Spec	5666
	pICSL01005-EFR L873E Y836F	This paper	Spec	5669
	pICSL01005-EFR D849N	This paper	Spec	6487
	pICSL01005-EFR F761H D849N	This paper	Spec	6341
	pICSL01005-EFR F761H SSAA	This paper	Spec	5662
	pICSL01005-EFR F761M SSAA	This paper	Spec	5664
	pICH41308-BAK1	This paper	Spec	2945
	pICH41308-BAK1 Y403F	This paper	Spec	6336
Level 1 – binary plasmids				
	pICSL86955	(Weber et al., 2011)	Kan/PPT	
	pICSL86955-pEFR::EFR-GFP::HSP18t	This paper	Kan/PPT	2930
	pICSL86955-pEFR::EFR Y836F-GFP::HSP18t	This paper	Kan/PPT	5640
	pICSL86955-pEFR::EFR SSAA-GFP::HSP18t	This paper	Kan/PPT	5646
	pICSL86955-pEFR::EFR F761H-GFP::HSP18t	This paper	Kan/PPT	5641
	pICSL86955-pEFR::EFR F761M-GFP::HSP18t	This paper	Kan/PPT	5642
	pICSL86955-pEFR::EFR dNLLKH-GFP::HSP18t	This paper	Kan/PPT	5644
	pICSL86955-pEFR::EFR L743F-GFP::HSP18t	This paper	Kan/PPT	5643
	pICSL86955-pEFR::EFR L873E-GFP::HSP18t	This paper	Kan/PPT	5639
	pICSL86955-pEFR::EFR F761H Y836F-GFP::HSP18t	This paper	Kan/PPT	5647
	pICSL86955-pEFR::EFR F761M Y836F-GFP::HSP18t	This paper	Kan/PPT	5649
	pICSL86955-pEFR::EFR dNLLKH Y836F-GFP::HSP18t	This paper	Kan/PPT	5652
	pICSL86955-pEFR::EFR L743F Y836F -GFP::HSP18t	This paper	Kan/PPT	5651
	pICSL86955-pEFR::EFR Y836F L873E-GFP::HSP18t	This paper	Kan/PPT	5639
	pICSL86955-pEFR::EFR F761H SSAA-GFP::HSP18t	This paper	Kan/PPT	5648
	pICSL86955-pEFR::EFR F761M SSAA-GFP::HSP18t	This paper	Kan/PPT	5650
Level 0 – intracellular domains for RiD constructs				
	p641	(Chiasson et al., 2019)	Gent	
	p641-EFR_icd	This paper	Gent	5610
	p641-EFR F761H_icd	This paper	Gent	5612

Table 7

List of plasmids generated and used in this study.

CZLp number indicates the stock number of the plasmid, in case materials are requested. Source information and bacterial resistance markers are indicated. Plasmid maps are available through a Zenodo repository (link: see data availability).

p641-EFR D849N_ icd	This paper	Gent	6333
p641-EFR F761H D849N_ icd	This paper	Gent	6334
p641-BAK1_ icd	This paper	Gent	5614
p641-BAK1 Y403F_ icd	This paper	Gent	5615
p641-BAK1 D416N_ icd	This paper	Gent	6380
Level 1 – assemblies of transcriptional units for RiD constructs			
pC1a1-35S::FRB-BAK1_ icd::HSP18t	This paper	Carb	6391
pC1a1-35S::FRB-BAK1 Y403F_ icd::HSP18t	This paper	Carb	6395
pC1a1-35S::FRB-BAK1 D416N_ icd::HSP18t	This paper	Carb	6393
pC1a2-35S::FKBP-EFR_ icd::HSP18t	This paper	Carb	6324
pC1a2-35S::FKBP-EFR F761H_ icd::HSP18t	This paper	Carb	6326
Level 2 – binary plasmids of RiD constructs			
pICSL4723	(Weber et al., 2011)	Kan	
pICSL4723-FRB-BAK1-FKBP-EFR	This paper	Kan	6417
pICSL4723-FRB-BAK1 D416N-FKBP-EFR	This paper	Kan	6685
pICSL4723-FRB-BAK1-FKBP-EFR F761H	This paper	Kan	6418
pICSL4723-FRB-BAK1 D416N-FKBP-EFR F761H	This paper	Kan	6686
pICSL4723-FRB-BAK1 Y403F-FKBP-EFR	This paper	Kan	6421
pICSL4723-FRB-BAK1 Y403F-FKBP-EFR F761H	This paper	Kan	6422
Level 1- binary plasmids for EFR ectodomain fusion			
pICSL86955-35S::EFRecto-ccdB-GFP::HSP18t	This paper	Kan/PPT	6448
pICSL86955-35S::EFRecto-Xlla2icd-mEGFP::HSP18t	This paper	Kan/PPT	6456
pICSL86955-35S::EFRecto-Xlla2 D803N-mEGFP::HSP18t	This paper	Kan/PPT	6457
pICSL86955-35S::EFRecto-Xlla3icd-mEGFP::HSP18t	This paper	Kan/PPT	6458
pICSL86955-35S::EFRecto-Xlla3 D838N-mEGFP::HSP18t	This paper	Kan/PPT	6459
pICSL86955-35S::EFRecto-Xlla4icd-mEGFP::HSP18t	This paper	Kan/PPT	6460
pICSL86955-35S::EFRecto-Xlla4 D856N-mEGFP::HSP18t	This paper	Kan/PPT	6461
pICSL86955-35S::EFRecto-Xlla5icd-mEGFP::HSP18t	This paper	Kan/PPT	5630
pICSL86955-35S::EFRecto-Xlla5 D839N-mEGFP::HSP18t	This paper	Kan/PPT	5631
pICSL86955-35S::EFRecto-Xlla6icd-mEGFP::HSP18t	This paper	Kan/PPT	6462
pICSL86955-35S::EFRecto-Xlla6 D840N-mEGFP::HSP18t	This paper	Kan/PPT	6463
pICSL86955-35S::EFRecto-FLS2icd-mEGFP::HSP18t	This paper	Kan/PPT	6476
pICSL86955-35S::EFRecto-FLS2 D997N-mEGFP::HSP18t	This paper	Kan/PPT	6477
pICSL86955-35S::EFRecto-EFRicd-mEGFP::HSP18t	This paper	Kan/PPT	6480
pICSL86955-35S::EFRecto-EFR D849N-mEGFP::HSP18t	This paper	Kan/PPT	6481
pICSL86955-35S::EFRecto-XA21icd-mEGFP::HSP18t	This paper	Kan/PPT	6478
pICSL86955-35S::EFRecto-XA21 D803N-mEGFP::HSP18t	This paper	Kan/PPT	6479
pICSL86955-35S::EFRecto-Aralyicd-mEGFP::HSP18t	This paper	Kan/PPT	6466
pICSL86955-35S::EFRecto-Araly D850N-mEGFP::HSP18t	This paper	Kan/PPT	6467
pICSL86955-35S::EFRecto-Brapaicd-mEGFP::HSP18t	This paper	Kan/PPT	6468
pICSL86955-35S::EFRecto-Brapa D846N-mEGFP::HSP18t	This paper	Kan/PPT	6469
pICSL86955-35S::EFRecto-Solycicd-mEGFP::HSP18t	This paper	Kan/PPT	6470
pICSL86955-35S::EFRecto-Solyc D883N-mEGFP::HSP18t	This paper	Kan/PPT	6471
pICSL86955-35S::EFRecto-Poptricd-mEGFP::HSP18t	This paper	Kan/PPT	6474
pICSL86955-35S::EFRecto-Poptr D848N-mEGFP::HSP18t	This paper	Kan/PPT	6475
pICSL86955-35S::EFRecto-Glymaicd-mEGFP::HSP18t	This paper	Kan/PPT	6472
pICSL86955-35S::EFRecto-GlymaD829N-mEGFP::HSP18t	This paper	Kan/PPT	6473

Table 7 (continued)

	Level 1 – heterologous expression for <i>in vitro</i> RiD kinase assay			
	pETGG	This paper	Kan	4916
	pETGG-6xHis-FKBP-EFR _{icd} -mEGFP	This paper	Kan	6526
	pETGG-6xHis-FKBP-EFR _{icd} D849N-mEGFP	This paper	Kan	6529
	pETGG-6xHis-FKBP-BRI1-mEGFP	This paper	Kan	6561
	pETGG-6xHis-FKBP-BRI1 D1009N-mEGFP	This paper	Kan	6562
	pETGG-6xHis-FKBP-FLS2-mEGFP	This paper	Kan	6559
	pETGG-6xHis-FKBP-FLS D997N-mEGFP	This paper	Kan	6560
	pETGG-6xHis-FKBP-XIIa5-mEGFP	This paper	Kan	6557
	pETGG-6xHis-FKBP-XIIa5 D839N-mEGFP	This paper	Kan	6558
	pETGG-6xHis-FRB-BAK1	This paper	Kan	6454
	pET28a(+)-6xHis-BIK1 D202N	This paper	Kan	4445

Table 7 (continued)

Name	Genetic background	Construct	Publication/ SALK/NASC	selection	CZLs
<i>efr-1</i>	<i>efr-1</i>	None	(Zipfel et al., 2006)/ SALK_044334/N544334	Kan	CZLs6575
EFR-GFP	<i>efr-1</i>	pICSL86955-pEFR::EFR-GFP::HSP18t	This paper	Kan/PPT	CZLs6576
F761H#2	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H-GFP::HSP18t	This paper	Kan/PPT	CZLs6577
F761H#7	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H-GFP::HSP18t	This paper	Kan/PPT	CZLs6578
Y836F#1	<i>efr-1</i>	pICSL86955-pEFR::EFR Y836F-GFP::HSP18t	This paper	Kan/PPT	CZLs6591
Y836F#4	<i>efr-1</i>	pICSL86955-pEFR::EFR Y836F-GFP::HSP18t	This paper	Kan/PPT	CZLs6592
F761H Y836F#1	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H Y836F-GFP::HSP18t	This paper	Kan/PPT	CZLs6595
F761H Y836F#5	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H Y836F-GFP::HSP18t	This paper	Kan/PPT	CZLs6571
SSAA#2	<i>efr-1</i>	pICSL86955-pEFR::EFR SSAA-GFP::HSP18t	This paper	Kan/PPT	CZLs6593
SSAA#7	<i>efr-1</i>	pICSL86955-pEFR::EFR SSAA-GFP::HSP18t	This paper	Kan/PPT	CZLs6594
F761H SSAA#2	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H SSAA-GFP::HSP18t	This paper	Kan/PPT	CZLs6597
F761H SSAA#7	<i>efr-1</i>	pICSL86955-pEFR::EFR F761H SSAA-GFP::HSP18t	This paper	Kan/PPT	CZLs6598

Table 8

Transgenic Arabidopsis used in this study

Phylogenetic analysis and tree visualization

Multiple sequence alignments were retrieved from a previous phylogenetic study of plant LRR-RKs (Dufayard et al., 2017 [DOI](#)). Specifically, the trimmed multiple sequence alignment for subfamily XIIa was retrieved. The retrieved MSA was used for building a phylogenetic tree using the IQ-TREE webserver (Kalyaanamoorthy et al., 2017 [DOI](#); Minh et al., 2020 [DOI](#); Trifinopoulos et al., 2016 [DOI](#)). The generated tree file was then used to visualize the tree in R using the ggtree package v3.8.2 (Yu et al., 2017 [DOI](#)).

Statistical analysis

In general, non-parametric Kruskal-Wallis tests with Dunn's post-hoc test (Benjamin-Hochberg correction) were applied in this study because either sample size were small, data was not normally distributed or variance between groups were not similar. Outliers shown in boxplots were not removed prior to statistical analysis.

Figures

Data availability

All HDX RAW data for wild type and Y836F EFR have been deposited to the ProteomeXchange Consortium via ProteomeXchange via the PRIDE (Perez-Riverol et al., 2022 [DOI](#)) with the dataset identifier PXD049215. Supplemental information, including plasmid maps, replication information, cropping information, gene IDs, protein sequences, and PDB files, are available through a Zenodo repository (DOI: 10.5281/zenodo.10577813).




Figure 1 – Supplement 1

EFR^{Y836F} compromises ligand-induced receptor complex activation.

Two-week old seedlings were mock treated or treated with 1 μM elf18 for 10 min. Immunoprecipitation was then performed with anti-GFP, and the resulting immunoprecipitates probed for BAK1 S612 phosphorylation. Phosphorylated BAK1 was found to co-immunoprecipitate with WT EFR-GFP but hardly with EFR^{Y836F}-GFP, indicating ligand-induced receptor complex activation.




Figure 2 - Supplement 1

VIa-Tyr forms H-bonds with the α C- β 4 loop in various predicted and solved structures.

Solved structures were retrieved from PDB. AlphaFold2 models for kinases in their active conformation were retrieved from (Faezov and Dunbrack, 2023 [DOI](#)). BAK1 and EFR models were predicted by AlphaFold2, using the complete intracellular domain. H-bonds were predicted in ChimeraX and distances are indicated.




Figure 2 – Supplement 2

Rational design of activating mutations in EFR and screen for functional recovery of EFR^{Y836F}.

A) Alignments of EFR with human kinases containing oncogenic, kinase activating mutations that stabilize the αC-helix in active-like conformation (described in Foster et al., 2016; Hu et al., 2015). Homologous sites in EFR are indicated by arrows with the residue number. B) Structural model of the EFR kinase domain from AlphaFold2 with homologous sites identified in the sequence alignment from A highlighted in teal (missense mutation) or red (deletion). EFR Y836 at the C-terminal end of the αE-helix is colored purple. C) Screening of the homology-based putatively activating EFR mutations for restoration of EFR^{Y836F} function in *N. benthamiana*. All putative activating mutations were functional at WT-like level except EFR^{ΔNLLKH}. Only EFR^{F761[HM]} could functionally recover EFR^{Y836F} as the oxidative burst was partially restored. D) EFR^{L873E} showed a WT-like oxidative burst but EFR^{L873E/Y836F} did not restore the oxidative burst. Outliers are indicated by asterisk in addition to the outlier itself and are included in statistical analysis; Statistical test: Kruskal-Wallis test ($p = 9.319 \times 10^{-6}$ in C, $p = 0.01242$ in D), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$). Groups with like lowercase letter designations are not statistically different.




Figure 2 Supplement 3

EFR A-loop phosphorylation sites may coordinate with basic residues from the β 3- α C loop and α C-helix.

A) In PKA (1ATP), the A-loop phosphorylation on T197 coordinates with H87 from the α C-helix. B) In EFR (AlphaFold2 (AF2) model), there are two basic residues extending downwards from β 3- α C loop (H748) and α C-helix (K752) that may coordinate with A-loop phosphorylation on S887 or S888.




Figure 3 – Supplement 1

Multiple immune signaling branches are partially restored in EFR^{F761H/Y836F} and EFR^{F761H/SSAA}.

Stable transgenic complementation lines in the Arabidopsis *efr-1* background were generated and physiological experiments conducted in the T3 generation (except for EFR^{F761H/Y836F} #5, which is a double insertion line in T2 generation). A) In the oxidative burst assay, EFR F761H restored oxidative burst in EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines. Two independent experiments were merged into one graph as WT controls showed comparable total oxidative burst. A third independent experiment was performed with similar results. Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p < 2.2 \times 10^{-16}$), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$) Groups with like letter designations are not statistically different. Alike oxidative burst assays, EFR F761H restored SGI (B) and MAPK activation (C) in EFR^{F761H/Y836F} and EFR^{F761H/SSAA} complementation lines. For SGI assays, four independent experiments with 5 nM elf18 treatment are shown. Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p < 2.2 \times 10^{-16}$), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$) Groups with like letter designations are not statistically different. For MAPK activation assays, a representative experiment is shown. Similar results were obtained in three more experiments.




Figure 4 – Supplement 1

Function of BAK1 Y403F is partially recovered by a regulatory spine mutation (I338H) that stabilizes the active-like conformation.

A) The RiD system was utilized to test the recovery of BAK1 Y403F by transient expression in *N. benthamiana*. The Y403F mutation in BAK1 diminished the oxidative burst, whereas BAK1 I338H displayed near WT-like responses. Combining the I338H and Y403F mutations, however, led to a partial recovery of oxidative burst. Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p < 2.247 \times 10^{-11}$), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$) Groups with like letter designations are not statistically different. B) SDS-PAGE analysis of protein levels in experiments 2 and 3 of A is shown. Protein accumulation data for experiment 1 was not collected.




Figure 4 - Supplement 2

EFR F761H accelerates the onset of the oxidative burst but requires the catalytic activity of BAK1.

A) Quantification of the time until the oxidative burst reaches its half maximum from experiments presented in [Figure 2B](#). Both putative activating mutations, F761H and F761M accelerate the onset of the oxidative burst. B) Time resolved oxidative burst assay. Presented curves are from replicate number three as a representative example. Graphs in A and B are based on data presented in [Figure 2B](#). Error bars represent standard error of the mean. C) EFR F761H requires the catalytic activity of BAK1 to induce the oxidative burst. Data from three independent experiments is merged in one graph. D) Protein accumulation of the RiD-tagged protein related to panel C. Statistical analysis in A and C: Outliers are indicated by an additional asterisk and included in statistical analysis. Statistical test: Kruskal-Wallis test ($p = 1.686 \times 10^{-8}$ in A, $p = 5.89910^{-8}$ in C), Dunn's post-hoc test with Benjamin-Hochberg correction ($p \leq 0.05$). Groups with like letter designations are not statistically different.




Figure 4 – Supplement 3

Protein accumulation for the oxidative burst assay in

Figure 4. Leaf discs were collected after the oxidative burst assay and protein were extracted by boiling in SDS-loading buffer followed by immunoblotting. Non-infiltrated leaf discs served as negative control.




Figure 5 - Supplement 1

XIIa5^{D839N} exhibits largely XIIa5WT-like characteristics.

A,B) Catalytic site mutation of XIIa5 exhibited the least delayed onset of oxidative burst. In A, quantification of the time to reach the half maximum of the oxidative burst is shown. The underlying data are the same as used for total oxidative burst in the main figure. In B, the actual oxidative burst curves are presented as average of six individual plants transiently expressing the indicated chimeric protein. Error bars represent standard error of the mean. C) A catalytic site mutation of XIIa5 did not negatively affect BIK1 trans-phosphorylation or BAK1 autophosphorylation. Experiments were performed as described in **Figure 1C**. D) Quantification of band intensities on autoradiographs from three independent experiments are shown. BRI1^{D1009N} and EFR^{D849N} displayed results similar to **Figure 1B,C**. In contrast to EFR^{D849N}, for which BIK1 and BAK1 relative band intensities slightly decreased compared to wild type EFR, BIK1^{D202N} and BAK1 relative band intensities were wild-type-like for XIIa5^{D839N}.




Figure 5 – Supplement 2

Protein accumulation of EFR-XIIa chimeras in *N. benthamiana*.

All constructs exhibited detectable protein accumulation in transiently transformed *N. benthamiana* leaves. Similar protein accumulation was observed in 3 replicates for A. Protein accumulation for constructs in B was tested once.

References

- Albrecht C., Russinova E., Kemmerling B., Kwaaitaal M., de Vries S.C. (2008) **Arabidopsis SOMATIC EMBRYOGENESIS RECEPTOR KINASE Proteins Serve Brassinosteroid-Dependent and - Independent Signaling Pathways** *Plant Physiol* **148**:611–619 <https://doi.org/10.1104/pp.108.123216>
- Banaszynski L.A., Liu C.W., Wandless T.J (2005) **Characterization of the FKBP-Rapamycin-FRB Ternary Complex** *J. Am. Chem. Soc* **127**:4715–4721 <https://doi.org/10.1021/ja043277y>
- Bender K.W. *et al.* (2021) **Activation loop phosphorylation of a non-RD receptor kinase initiates plant innate immune signaling** *Proc. Natl. Acad. Sci* **118** <https://doi.org/10.1073/pnas.2108242118>
- Bender K.W., Zipfel C (2023) **Paradigms of receptor kinase signaling in plants** *Biochem. J* **480**:835–854 <https://doi.org/10.1042/BCJ20220372>
- Cao Y., Aceti D.J., Sabat G., Song J., Makino S., Fox B.G., Bent A.F (2013) **Mutations in FLS2 Ser-938 Dissect Signaling Activation in FLS2-Mediated Arabidopsis Immunity** *PLoS Pathog* **9** <https://doi.org/10.1371/journal.ppat.1003313>
- Chiasson D. *et al.* (2019) **A unified multi-kingdom Golden Gate cloning platform** *Sci. Rep* **9** <https://doi.org/10.1038/s41598-019-46171-2>
- Clough S.J., Bent A.F (1998) **Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana**. *Plant J Cell Mol. Biol* **16**:735–743 <https://doi.org/10.1046/j.1365-313x.1998.00343.x>
- Couto D., Zipfel C (2016) **Regulation of pattern recognition receptor signalling in plants** *Nat. Rev. Immunol* **16**:537–552 <https://doi.org/10.1038/nri.2016.77>
- Davis A.M., Hall A., Millar A.J., Darrah C., Davis S.J (2009) **Protocol: Streamlined sub-protocols for floral-dip transformation and selection of transformants in Arabidopsis thaliana** *Plant Methods* **5** <https://doi.org/10.1186/1746-4811-5-3>
- DeFalco T.A., Zipfel C (2021) **Molecular mechanisms of early plant pattern-triggered immune signaling** *Mol. Cell* **81**:3449–3467 <https://doi.org/10.1016/j.molcel.2021.07.029>
- Dufayard J.-F., Bettembourg M., Fischer I., Droc G., Guiderdoni E., Périn C., Chantret N., Diévert A (2017) **New Insights on Leucine-Rich Repeats Receptor-Like Kinase Orthologous Relationships in Angiosperms** *Front. Plant Sci* **8**
- Faezov B., Dunbrack R.L (2023) **AlphaFold2 models of the active form of all 437 catalytically-competent typical human kinase domains** <https://doi.org/10.1101/2023.07.21.550125>
- Foster S.A. *et al.* (2016) **Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2** *Cancer Cell* **29**:477–493 <https://doi.org/10.1016/j.ccell.2016.02.010>
- Gómez-Gómez L., Boller T (2000) **FLS2: An LRR Receptor-like Kinase Involved in the Perception of the Bacterial Elicitor Flagellin in Arabidopsis** *Mol. Cell* **5**:1003–1011 [https://doi.org/10.1016/S1097-2765\(00\)80265-8](https://doi.org/10.1016/S1097-2765(00)80265-8)

- He Z., Wang Z.-Y., Li J., Zhu Q., Lamb C., Ronald P., Chory J (2000) **Perception of Brassinosteroids by the Extracellular Domain of the Receptor Kinase BRI1** *Science* **288**:2360–2363 <https://doi.org/10.1126/science.288.5475.2360>
- Hohmann U., Lau K., Hothorn M (2017) **The Structural Basis of Ligand Perception and Signal Activation by Receptor Kinases** *Annu. Rev. Plant Biol* **68**:109–137 <https://doi.org/10.1146/annurev-arplant-042916-040957>
- Hothorn M., Belkhadir Y., Dreux M., Dabi T., Noel J.P., Wilson I.A., Chory J (2011) **Structural basis of steroid hormone perception by the receptor kinase BRI1** *Nature* **474**:467–471 <https://doi.org/10.1038/nature10153>
- Houde D., Berkowitz S.A., Engen J.R (2011) **The Utility of Hydrogen/Deuterium Exchange Mass Spectrometry in Biopharmaceutical Comparability Studies** *J. Pharm. Sci* **100**:2071–2086 <https://doi.org/10.1002/jps.22432>
- Hu J., Ahuja L.G., Meharena H.S., Kannan N., Kornev A.P., Taylor S.S., Shaw A.S (2015) **Kinase Regulation by Hydrophobic Spine Assembly in Cancer** *Mol. Cell. Biol* **35**:264–276 <https://doi.org/10.1128/MCB.00943-14>
- Hu J., Stites E.C., Yu H., Germino E.A., Meharena H.S., Stork P.J.S., Kornev A.P., Taylor S.S., Shaw A.S (2013) **Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers** *Cell* **154**:1036–1046 <https://doi.org/10.1016/j.cell.2013.07.046>
- Jumper J. *et al.* (2021) **Highly accurate protein structure prediction with AlphaFold** *Nature* **596**:583–589 <https://doi.org/10.1038/s41586-021-03819-2>
- Kalyaanamoorthy S., Minh B.Q., Wong T.K.F., von Haeseler A., Jermin L.S. (2017) **ModelFinder: fast model selection for accurate phylogenetic estimates** *Nat. Methods* **14**:587–589 <https://doi.org/10.1038/nmeth.4285>
- Kim S., Park J., Jeon B.W., Hwang G., Kang N.Y., We Y., Park W.-Y., Oh E., Kim J (2021) **Chemical control of receptor kinase signaling by rapamycin-induced dimerization** *Mol. Plant* **14**:1379–1390 <https://doi.org/10.1016/j.molp.2021.05.006>
- Kosentka P.Z., Zhang L., Simon Y.A., Satpathy B., Maradiaga R., Mitoubsi O., Shpak E.D (2017) **Identification of critical functional residues of receptor-like kinase ERECTA** *J. Exp. Bot* **68**:1507–1518 <https://doi.org/10.1093/jxb/erx022>
- Kwon A., Scott S., Taujale R., Yeung W., Kochut K.J., Evers P.A., Kannan N (2019) **Tracing the origin and evolution of pseudokinases across the tree of life** *Sci. Signal* **12** <https://doi.org/10.1126/scisignal.aav3810>
- Lai S., Safaei J., Pelech S (2016) **Evolutionary Ancestry of Eukaryotic Protein Kinases and Choline Kinases** *J. Biol. Chem* **291**:5199–5205 <https://doi.org/10.1074/jbc.M115.691428>
- Lemmon M.A., Schlessinger J (2010) **Cell Signaling by Receptor Tyrosine Kinases** *Cell* **141**:1117–1134 <https://doi.org/10.1016/j.cell.2010.06.011>
- Li L. *et al.* (2014) **The FLS2-Associated Kinase BIK1 Directly Phosphorylates the NADPH Oxidase RbohD to Control Plant Immunity** *Cell Host Microbe* **15**:329–338 <https://doi.org/10.1016/j.chom.2014.02.009>

- Lin W., Lu D., Gao X., Jiang S., Ma X., Wang Z., Mengiste T., He P., Shan L (2013) **Inverse modulation of plant immune and brassinosteroid signaling pathways by the receptor-like cytoplasmic kinase BIK1** *Proc. Natl. Acad. Sci. U. S. A* **110**:12114–12119 <https://doi.org/10.1073/pnas.1302154110>
- Liu H., Naismith J.H (2008) **An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol** *BMC Biotechnol* **8** <https://doi.org/10.1186/1472-6750-8-91>
- Liu J. *et al.* (2018) **A Tyrosine Phosphorylation Cycle Regulates Fungal Activation of a Plant Receptor Ser/Thr Kinase** *Cell Host Microbe* **23**:241–253 <https://doi.org/10.1016/j.chom.2017.12.005>
- Lu D., Wu S., Gao X., Zhang Y., Shan L., He P (2010) **A receptor-like cytoplasmic kinase, BIK1, associates with a flagellin receptor complex to initiate plant innate immunity** *Proc. Natl. Acad. Sci. U. S. A.* **107**:496–501 <https://doi.org/10.1073/pnas.0909705107>
- Luo X., Wu W., Liang Y., Xu N., Wang Z., Zou H., Liu J (2020) **Tyrosine phosphorylation of the lectin receptor-like kinase LORE regulates plant immunity** *EMBO J* **39** <https://doi.org/10.15252/embj.2019102856>
- Mace P.D., Murphy J.M (2021) **There’s more to death than life: Noncatalytic functions in kinase and pseudokinase signaling** *J. Biol. Chem* **296** <https://doi.org/10.1016/j.jbc.2021.100705>
- Macho A.P. *et al.* (2014) **A Bacterial Tyrosine Phosphatase Inhibits Plant Pattern Recognition Receptor Activation** *Science* **343**:1509–1512 <https://doi.org/10.1126/science.1248849>
- Man J., Harrington T., Lally K., Bartlett M.E (2023) **Asymmetric evolution of protein domains in the leucine-rich repeat receptor-like kinase (LRR-RLK) family of plant developmental coordinators** <https://doi.org/10.1101/2023.03.13.532436>
- Masson G.R. *et al.* (2019) **Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments** *Nat. Methods* **16**:595–602 <https://doi.org/10.1038/s41592-019-0459-y>
- Meharena H.S., Fan X., Ahuja L.G., Keshwani M.M., McClendon C.L., Chen A.M., Adams J.A., Taylor S.S (2016) **Decoding the Interactions Regulating the Active State Mechanics of Eukaryotic Protein Kinases** *PLOS Biol* **14** <https://doi.org/10.1371/journal.pbio.2000127>
- Mills J.E.J., Dean P.M (1996) **Three-dimensional hydrogen-bond geometry and probability information from a crystal survey** *J. Comput. Aided Mol. Des* **10**:607–622 <https://doi.org/10.1007/BF00134183>
- Minh B.Q., Schmidt H.A., Chernomor O., Schrempf D., Woodhams M.D., von Haeseler A., Lanfear R. (2020) **IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era** *Mol. Biol. Evol* **37**:1530–1534 <https://doi.org/10.1093/molbev/msaa015>
- Mirdita M., Schütze K., Moriwaki Y., Heo L., Ovchinnikov S., Steinegger M (2022) **ColabFold - Making protein folding accessible to all** <https://doi.org/10.1101/2021.08.15.456425>

- Moffett A.S., Bender K.W., Huber S.C., Shukla D (2017) **Molecular dynamics simulations reveal the conformational dynamics of Arabidopsis thaliana BRI1 and BAK1 receptor-like kinases** *J. Biol. Chem* **292**:12643–12652 <https://doi.org/10.1074/jbc.M117.792762>
- Mott G.A., Thakur S., Smakowska E., Wang P.W., Belkhadir Y., Desveaux D., Guttman D.S (2016) **Genomic screens identify a new phyto bacterial microbe-associated molecular pattern and the cognate Arabidopsis receptor-like kinase that mediates its immune elicitation** *Genome Biol* **17** <https://doi.org/10.1186/s13059-016-0955-7>
- Nam K.H., Li J (2002) **BRI1/BAK1, a Receptor Kinase Pair Mediating Brassinosteroid Signaling** *Cell* **110**:203–212 [https://doi.org/10.1016/S0092-8674\(02\)00814-0](https://doi.org/10.1016/S0092-8674(02)00814-0)
- Oh M.-H., Wang X., Kota U., Goshe M.B., Clouse S.D., Huber S.C (2009) **Tyrosine phosphorylation of the BRI1 receptor kinase emerges as a component of brassinosteroid signaling in Arabidopsis** *Proc. Natl. Acad. Sci* **106**:658–663 <https://doi.org/10.1073/pnas.0810249106>
- Olivieri C. *et al.* (2023) **The α C- β 4 loop controls the allosteric cooperativity between nucleotide and substrate in the catalytic subunit of protein kinase A** <https://doi.org/10.1101/2023.09.12.557419>
- Perez-Riverol Y. *et al.* (2022) **The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences** *Nucleic Acids Res* **50**:D543–D552 <https://doi.org/10.1093/nar/gkab1038>
- Perraki A. *et al.* (2018) **Phosphocode-dependent functional dichotomy of a common co-receptor in plant signalling** *Nature* **561**:248–252 <https://doi.org/10.1038/s41586-018-0471-x>
- Pettersen E.F., Goddard T.D., Huang C.C., Meng E.C., Couch G.S., Croll T.I., Morris J.H., Ferrin T.E (2021) **UCSF ChimeraX: Structure visualization for researchers, educators, and developers** *Protein Sci* **30**:70–82 <https://doi.org/10.1002/pro.3943>
- Ranf S., Eschen-Lippold L., Fröhlich K., Westphal L., Scheel D., Lee J (2014) **Microbe-associated molecular pattern-induced calcium signaling requires the receptor-like cytoplasmic kinases, PBL1 and BIK1** *BMC Plant Biol.* **14** <https://doi.org/10.1186/s12870-014-0374-4>
- Rhodes J., Yang H., Moussu S., Boutrot F., Santiago J., Zipfel C (2021) **Perception of a divergent family of phytocytokines by the Arabidopsis receptor kinase MIK2** *Nat. Commun* **12** <https://doi.org/10.1038/s41467-021-20932-y>
- Roux M., Schwessinger B., Albrecht C., Chinchilla D., Jones A., Holton N., Malinovsky F.G., Tör M., de Vries S., Zipfel C. (2011) **The Arabidopsis Leucine-Rich Repeat Receptor-Like Kinases BAK1/SERK3 and BKK1/SERK4 Are Required for Innate Immunity to Hemibiotrophic and Biotrophic Pathogens** *Plant Cell* **23**:2440–2455 <https://doi.org/10.1105/tpc.111.084301>
- Santiago J., Henzler C., Hothorn M (2013) **Molecular mechanism for plant steroid receptor activation by somatic embryogenesis co-receptor kinases** *Science* **341**:889–892 <https://doi.org/10.1126/science.1242468>
- Schmidt S.H. *et al.* (2021) **Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2** *Proc. Natl. Acad. Sci* **118** <https://doi.org/10.1073/pnas.2100844118>

- Schulze B., Mentzel T., Jehle A.K., Mueller K., Beeler S., Boller T., Felix G., Chinchilla D (2010) **Rapid Heteromerization and Phosphorylation of Ligand-activated Plant Transmembrane Receptors and Their Associated Kinase BAK1*** *J. Biol. Chem* **285**:9444–9451 <https://doi.org/10.1074/jbc.M109.096842>
- Schwessinger B., Roux M., Kadota Y., Ntoukakis V., Sklenar J., Jones A., Zipfel C (2011) **Phosphorylation-Dependent Differential Regulation of Plant Growth, Cell Death, and Innate Immunity by the Regulatory Receptor-Like Kinase BAK1** *PLoS Genet* **7** <https://doi.org/10.1371/journal.pgen.1002046>
- Segonzac C., Macho A.P., Sanmartín M., Ntoukakis V., Sánchez-Serrano J.J., Zipfel C (2014) **Negative control of BAK1 by protein phosphatase 2A during plant innate immunity** *EMBO J* **33**:2069–2079 <https://doi.org/10.15252/embj.201488698>
- Sheetz J.B., Lemmon M.A (2022) **Looking lively: emerging principles of pseudokinase signaling** *Trends Biochem. Sci* **47**:875–891 <https://doi.org/10.1016/j.tibs.2022.04.011>
- Sheetz J.B. *et al.* (2020) **Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases** *Mol. Cell* **79**:390–405 <https://doi.org/10.1016/j.molcel.2020.06.018>
- Shiu S.-H., Bleecker A.B (2003) **Expansion of the Receptor-Like Kinase/Pelle Gene Family and Receptor-Like Proteins in Arabidopsis** *Plant Physiol* **132**:530–543 <https://doi.org/10.1104/pp.103.021964>
- Shiu S.-H., Bleecker A.B (2001) **Receptor-like kinases from Arabidopsis form a monophyletic gene family related to animal receptor kinases** *Proc. Natl. Acad. Sci* **98**:10763–10768 <https://doi.org/10.1073/pnas.181141598>
- Taylor I., Wang Y., Seitz K., Baer J., Bennewitz S., Mooney B.P., Walker J.C (2016) **Analysis of Phosphorylation of the Receptor-Like Protein Kinase HAESA during Arabidopsis Floral Abscission** *PLoS ONE* **11** <https://doi.org/10.1371/journal.pone.0147203>
- Taylor S.S., Kornev A.P (2011) **Protein kinases: evolution of dynamic regulatory proteins** *Trends Biochem. Sci* **36**:65–77 <https://doi.org/10.1016/j.tibs.2010.09.006>
- Trifinopoulos J., Nguyen L.-T., von Haeseler A., Minh B.Q. (2016) **W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis** *Nucleic Acids Res* **44**:W232–W235 <https://doi.org/10.1093/nar/gkw256>
- Trusov Y., Botella J.R (2016) **Plant G-Proteins Come of Age: Breaking the Bond with Animal Models** *Front. Chem* **4**
- Tsigelny I., Greenberg J.P., Cox S., Nichols W.L., Taylor S.S., Ten Eyck L.F (1999) **600 ps Molecular dynamics reveals stable substructures and flexible hinge points in cAMP dependent protein kinase** *Biopolymers* **50**:513–524 [https://doi.org/10.1002/\(SICI\)1097-0282\(19991015\)50:5<513::AID-BIP5>3.0.CO;2-I](https://doi.org/10.1002/(SICI)1097-0282(19991015)50:5<513::AID-BIP5>3.0.CO;2-I)
- Wang X., Goshe M.B., Soderblom E.J., Phinney B.S., Kuchar J.A., Li J., Asami T., Yoshida S., Huber S.C., Clouse S.D (2005) **Identification and Functional Analysis of in Vivo Phosphorylation Sites of the Arabidopsis BRASSINOSTEROID-INSENSITIVE1 Receptor Kinase** *Plant Cell* **17**:1685–1703 <https://doi.org/10.1105/tpc.105.031393>

- Wang X., Kota U., He K., Blackburn K., Li J., Goshe M.B., Huber S.C., Clouse S.D (2008) **Sequential Transphosphorylation of the BRI1/BAK1 Receptor Kinase Complex Impacts Early Events in Brassinosteroid Signaling** *Dev. Cell* **15**:220–235 <https://doi.org/10.1016/j.devcel.2008.06.011>
- Wang Y., Li Z., Liu D., Xu J., Wei X., Yan L., Yang C., Lou Z., Shui W (2014) **Assessment of BAK1 activity in different plant receptor-like kinase complexes by quantitative profiling of phosphorylation patterns** *J. Proteomics* **108**:484–493 <https://doi.org/10.1016/j.jprot.2014.06.009>
- Weber E., Engler C., Gruetzner R., Werner S., Marillonnet S (2011) **A Modular Cloning System for Standardized Assembly of Multigene Constructs** *PLOS ONE* **6** <https://doi.org/10.1371/journal.pone.0016765>
- Wernimont A.K. *et al.* (2010) **Structures of apicomplexan calcium-dependent protein kinases reveal mechanism of activation by calcium** *Nat. Struct. Mol. Biol* **17**:596–601 <https://doi.org/10.1038/nsmb.1795>
- Wu J., Jonniya N.A., Hirakis S.P., Olivieri C., Veglia G., Kornev A.P., Taylor S.S (2023) **Protein Kinase Structure and Dynamics: Role of the α C- β 4 Loop** <https://doi.org/10.1101/2023.08.31.555822>
- Yu G., Smith D.K., Zhu H., Guan Y., Lam T.T.-Y (2017) . **ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data** *Methods Ecol. Evol* **8**:28–36 <https://doi.org/10.1111/2041-210X.12628>
- Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J (2006) **An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor** *Cell* **125**:1137–1149 <https://doi.org/10.1016/j.cell.2006.05.013>
- Zipfel C., Kunze G., Chinchilla D., Caniard A., Jones J.D.G., Boller T., Felix G (2006) **Perception of the Bacterial PAMP EF-Tu by the Receptor EFR Restricts Agrobacterium-Mediated Transformation** *Cell* **125**:749–760 <https://doi.org/10.1016/j.cell.2006.03.037>

Article and author information

Henning Mühlenbeck

Institute of Plant and Microbial Biology, Zürich-Basel Plant Science Center, University of Zürich, 8008 Zürich, Switzerland

Yuko Tsutsui

Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA, Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT, 06516, USA

Mark A. Lemmon

Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA, Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT, 06516, USA

Kyle W. Bender

Institute of Plant and Microbial Biology, Zürich-Basel Plant Science Center, University of Zürich, 8008 Zürich, Switzerland

For correspondence: kyle.bender@uzh.ch

ORCID iD: [0000-0002-1805-8097](https://orcid.org/0000-0002-1805-8097)

Cyril Zipfel

Institute of Plant and Microbial Biology, Zürich-Basel Plant Science Center, University of Zürich, 8008 Zürich, Switzerland, The Sainsbury Laboratory, University of East Anglia, Norwich Research Park, NR4 7UH Norwich, U.K

For correspondence: cyril.zipfel@uzh.ch

ORCID iD: [0000-0003-4935-8583](https://orcid.org/0000-0003-4935-8583)

Copyright

© 2023, Mühlenbeck et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Volker Dötsch

Goethe University, Frankfurt am Main, Germany

Senior Editor

Volker Dötsch

Goethe University, Frankfurt am Main, Germany

Reviewer #1 (Public Review):**Summary**

The authors use an elegant but somewhat artificial heterodimerisation approach to activate the isolated cytoplasmic domains of different receptor kinases (RKs) including the receptor kinase BRI1 and EFR. The developmental RK BRI1 is known to be activated by the co-receptor BAK1. Active BRI1 is then able to phosphorylate downstream substrates. The immune receptor EFR is also an active protein kinase also activated by the co-receptor BAK1. EFR however appears to have little or no kinase activity but seems to use an allosteric mechanism to in turn enable BAK1 to phosphorylate the substrate kinase BIK1. EFR tyrosine phosphorylation by BAK1 appears to trigger a conformational change in EFR, activating the receptor. Likewise, kinase activating mutations can cause similar conformational transitions in EFR and also in BAK1 in vitro and in planta.

Strengths:

I particularly liked The HDX experiments coupled with mutational analysis (Fig. 2) and the design and testing of the kinase activating mutations (Fig. 3), as they provide novel mechanistic insights into the activation mechanisms of EFR and of BAK1. These findings are nicely extended by the large-scale identification of EFR-related RKs from different species with potentially similar activation mechanisms (Fig. 5).

Weaknesses:

In my opinion, there are currently two major issues with the present manuscript. (1) The authors have previously reported that the EFR kinase activity is dispensable for immune signaling (<https://pubmed.ncbi.nlm.nih.gov/34531323/>) but the wild-type EFR receptor still leads to a much better phosphorylation of the BIK1 substrate when compared to the kinase inactive D849N mutant protein (Fig. 1). (2) How the active-like conformation of EFR is in turn activating BAK1 is poorly characterized, but appears to be the main step in the activation of the receptor complex. Extending the HDX analyses to resting and Rap-activated receptor complexes could be a first step to address this question, but these HDX studies were not carried out due to technical limitations.

Overall this is an interesting study that aims to advance our understanding of the activation mechanisms of different plant receptor kinases with important functions in plant immunity.

<https://doi.org/10.7554/eLife.92110.2.sa2>

Reviewer #2 (Public Review):

Summary:

Transmembrane signaling in plants is crucial for homeostasis. In this study, the authors set out to understand to what extent catalytic activity in the EFR tyrosine kinase is required in order to transmit a signal. This work was driven by mounting data that suggest many eukaryotic kinases do not rely on catalysis for signal transduction, relying instead on conformational switching to relay information. The crucial findings reported here involve the realisation that a kinase-inactive EFR can still activate (ie lead to downstream phosphorylation) of its partner protein BAK1. Using a convincing set of biochemical, mass spectrometric (HD-exchange) and in vivo assays, the team suggest a model in which EFR is likely phosphorylated in the canonical activation segment (where two Ser residues are present), which is sufficient to generate a conformation that can activate BAK1 through dimersation. A model is put forward involving C-helix positioning in BAK1, and the model extended to other 'non-RD' kinases in Arabidopsis kinases that likely do not require kinase activity for signaling.

Strengths:

The work uses logical and well-controlled approaches throughout, and is clear and convincing in most areas, linking data from IPs, kinase assays (including clear ³²P-based biochemistry), HD-MX data (from non-phosphorylated EFR) structural biology, oxidative burst data and infectivity assays. Repetitions and statistical analysis all appear appropriate. Overall, the work builds a convincing story and the discussion does a clear job of explaining the potential impact of these findings (and perhaps an explanation of why so many Arabidopsis kinases are 'pseudokinases', including XPS1 and XIIa6, where this is shown explicitly).

Weaknesses:

No major weaknesses are noted from reviewing the data and the paper follows a logical course built on solid foundations; the use of Tables to explain various experimental data pertinent to the reported studies is appreciated.

(1) The use of a, b, c, d in Figures 2C and 3C etc is confusing to this referee, and is now addressed in the latest version

(2) The debate about kinase v pseudokinases is well over a decade old. For non-experts, the

- kinase alignments/issues raised are in PMID: 23863165 and might prove useful if cited.
- (3) Early on in the paper, the concept of kinases and pseudokinases related to R-spine (and extended R-spine) stability and regulation really needs to be more adequately introduced to explain what comes next; e.g. some of the key work in this area for RAF and Tyr kinases where mutual F-helix Phe amino acid changes are evaluated (conceptually similar to this study of the E-helix Tyr to Phe changes in EFR) should be cited (PMID: 17095602, 24567368 and 26925779).
- (4) In my version, some of the experimental text is also currently in the wrong order (and no page numbers, so hard for me to state exactly where in the manuscript); However, I am certain that Figure 2C is mentioned in the text when the data are actually shown in Figure 3C for the EFR-SSAA protein.
- (5) Tyr 156 in PKA is not shown in Supplement 1, 2A as suggested in the text; for readers, it will be important to show the alignment of the Tyr residue in other kinases; this has been updated in the second version. Although it is clearly challenging to generate phosphorylated EFR (seemingly through Codon-expansion here?), it appears unlikely that a phosphorylated EFR protein, even semi-pure, couldn't have been assayed to test the idea that the phosphorylation drives/supports downstream signaling. What about a DD or EE mutation, as commonly used (perhaps over-used) in MEK-type studies?

Impact:

The work is an important new step in the huge amount of follow-up work needed to examine how kinases and pseudokinases 'talk' to each other in (especially) the plant kingdom, where significant genetic expansions have occurred. The broader impact is that we might understand better how to manipulate signaling for the benefit of plants and mankind; as the authors suggest, their study is a natural progression both of their own work, and the kingdom-wide study of the Kannan group.

<https://doi.org/10.7554/eLife.92110.2.sa1>

Reviewer #3 (Public Review):

The study presents strong evidence for allosteric activation of plant receptor kinases, which enhances our understanding of the non-catalytic mechanisms employed by this large family of receptors.

Plant receptor kinases (RKs) play a critical role in transducing extracellular signals. The activation of RKs involves homo- or heterodimerization of the RKs, and it is believed that mutual phosphorylation of their intracellular kinase domains initiates downstream signaling. However, this model faces a challenge in cases where the kinase domain exhibits pseudokinase characteristics. In their recent study, Mühlenbeck et al. reveal the non-catalytic activation mechanisms of the EFR-BAK1 complex in plant receptor kinase signaling. Specifically, they aimed to determine that the EFR kinase domain activates BAK1 not through its kinase activity, but rather by utilizing a "conformational toggle" mechanism to enter an active-like state, enabling allosteric trans-activation of BAK1. The study sought to elucidate the structural elements and mutations of EFR that affect this conformational switch, as well as explore the implications for immune signaling in plants. To investigate the activation mechanisms of the EFR-BAK1 complex, the research team employed a combination of mutational analysis, structural studies, and hydrogen-deuterium exchange mass spectrometry (HDX-MS) analysis. For instance, through HDX-MS analysis, Mühlenbeck et al. discovered that the EFR (Y836F) mutation impairs the accessibility of the active-like conformation. On the other hand, they identified the EFR (F761H) mutation as a potent intragenic suppressor capable of stabilizing the active-like conformation, highlighting the pivotal role of allosteric regulation in BAK1 kinase activation. The data obtained from this methodology strengthens their major conclusion. Moreover, the researchers propose that the

allosteric activation mechanism may extend beyond the EFR-BAK1 complex, as it may also be partially conserved in the Arabidopsis LRR-RK XIIa kinases. This suggests a broader role for non-catalytic mechanisms in plant RK signaling.

The allosteric activation mechanism was demonstrated for receptor tyrosine kinases (RTKs) many years ago. A similar mechanism has been suggested for the activation of plant RKs, but experimental evidence for this conclusion is lacking. Data in this study represent a significant advancement in our understanding of non-catalytic mechanisms in plant RK signaling. By shedding light on the allosteric regulation of BAK1, the study provides a new paradigm for future research in this area.

<https://doi.org/10.7554/eLife.92110.2.sa0>

Author response:

The following is the authors' response to the original reviews.

Reviewer #1:

I will summarize my comments and suggestions below.

(1) Abstract:

"Non-catalytic (pseudo)kinase signaling mechanisms have been described in metazoans, but information is scarce for plants." To the best of my understanding EFR is an active protein kinase in vitro and in vivo and cannot be considered a pseudokinase. Consider rephrasing.

We rephrased to: "Non-catalytic signaling mechanisms of protein kinase domains have been described in metazoans, but information is scarce for plants."

(2) Page 4: It should be noted, that while membrane associated Rap-RiD systems have been used in planta to activate receptor kinase intracellular domains by promoting interaction with a co-receptor kinase domain, this system does not resemble the actual activation mechanism in the plasma membrane. This would be worth discussing when introducing the system. For example, the first substrates of the RK signaling complex may also be membrane associated and not freely diffuse in solution, which may be important for enzyme-substrate interaction.

We inserted on page 4: "The RiD system was previously applied in planta, maintaining membrane-association by N-terminal myristoylation (Kim et al., 2021). For the in vitro experiments, the myristoylation sites were excluded to facilitate the production of recombinant protein."

(3) Page 4 and Fig 1: The catalytic Asp in BRI1 is D1027 and not D1009 (<https://pubmed.ncbi.nlm.nih.gov/21289069/>). Please check and prepare the correct mutant protein if needed.

We clarified this in the text by stating that we mutated the HRD-aspartate to asparagine in all our catalytic-dead mutants: "Kinase-dead variants with the catalytic residue (HRD-aspartate) replaced by asparagine (EFRD849N and BRI1D1009N), had distinct effects [...]". D1027 in BRI1 is the DFG-Asp, which was not mutated in our study.

(4) Page 4 and Fig 1: Is BIK1 a known component of the BR signaling pathway and a direct BRI1 substrate? Or in other words how specific is the trans-phosphorylation assay?

In my opinion, a more suitable substrate for BRI1/BAK1 would be BSK1 or BSK3 (for example <https://pubmed.ncbi.nlm.nih.gov/30615605/>).

Kinase-dead BIK1 is a reported substrate of BRI1. We clarified this in the results section by inserting: “BIK1 was chosen as it is reported substrate of both, EFR/BAK1 and BRI1/BAK1 complexes (Lin et al., 2013).”

(5) Fig. 1B Why is BIK1 D202N partially phosphorylated in the absence of Rap? I would suggest to add control lanes showing BRI1, EFR, FLS2, BAK1 and BIK1 in isolation. Given that a nice in vitro activation system with purified components is available, why not compare the different enzyme kinetics rather than band intensities at only 1 enzyme : substrate ratio?

BIK1 D202N is partially phosphorylated due to the presence of active BAK1 that is capable of transphosphorylating BIK1 D202N as it has been reported in a previous study: (DOI: 10.1038/s41586-018-0471-x).

(6) Page 4 and Fig 1: Is the kinase dead variant of EFR indeed kinase dead? I could still see a decent autorad signal for this mutant when expressed in E. coli (Fig 1 A in Bender et al., 2021; <https://pubmed.ncbi.nlm.nih.gov/34531323/>)? If this mutant is not completely inactive, could this change the interpretation of the experiments performed with the mutant protein in vitro and in planta in the current manuscript? In my opinion, it could be possible that a partially active EFR mutant can be further activated by BAK1, and in turn can phosphorylate BIK1 D202N. The differences in autorad signal for BRI1D1009?N and EFRD849N is very small, and the entire mechanism hinges on this difference.

We would like to emphasize that the mechanism hinges on the difference between non-dimerized and dimerized kinase domains in the in vitro kinase assay. BRI1 D1009N fails to enhance BIK1 D202N trans-phosphorylation compared to the non-dimerized sample, while EFR D849N is still capable of enhancing BIK1 transphosphorylation upon dimerization as indicated by quantification of autorads (Figure 1B/C). We have also addressed this point in a section on the limitations of our study.

(7) Fig 1B. "Our findings therefore support the hypothesis that EFR increases BIK1 phosphorylation by allosterically activating the BAK1 kinase domain." To the best of my understanding presence of wild-type EFR in the EFR-BAK1 signaling complex leads to much better phosphorylation of BIK1D202N when compared to the EFRD849N mutant. How does that support the allosteric mechanism? By assuming that the D849N mutant is in an inactive conformation and fully catalytically inactive (see above)? Again, I think the data could also be interpreted in such a way that the small difference in autorad signal for BIK1 between BRI1 inactive (but see above) and EFR inactive are due to EFR not being completely kinase dead (see above), rather than EFR being an allosteric regulator. To clarify this point I would suggest to a) perform quantitative auto- and trans-(generic substrate) phosphorylation assays with wt and D849N EFR to derive enzyme kinetic parameters, to (2) include the EFRD849 mutant in the HDX analysis and (3) to generate transgenic lines for EFRD489N/F761H/Y836F // EFRD489N/F761H/SSAA and compare them to the existing lines in Fig. 3.

Mutations of proteins, especially those that require conformational plasticity for their function can have pleiotropic effects as the mutation may affect the conformational plasticity and consequently catalytic and non-catalytic functions that depend on the conformational plasticity. In such cases, it is difficult to fully untangle catalytic and non-catalytic functions. Coming back to EFR D849N, the D849N mutation may also impact the non-catalytic function by altering the conformational plasticity, explaining the difference observed in EFR vs EFR

D849N. As you rightly suggested, HDX would be a way to address this but would still not clarify whether catalytic activity contributes to activation. We instead attempted to produce analog sensitive EFR variants for in vivo characterization of EFR-targeted catalytic inhibition. Unfortunately, we failed in producing an analog-sensitive variant for which we could show ATP-analog binding. To address your concern, we inserted a section on limitations of the study.

(8) Fig. 2B,C, supplement 3 C,D. Has it been assessed if the different EFR versions were expressed to similar protein levels and still localized to the PM?


Localization of the mutant receptors has not been explicitly evaluated by confocal microscopy. However, the selected mutation EFRF761H is shown to accumulate in stable Arabidopsis lines (Figure 3 – Supplement 1C) and BAK1 could be coIPed by all EFR variants upon elf18-treatment (Figure 3 B), indicating plasma membrane localization.

(9) How the active-like conformation of EFR is in turn activating BAK1 is poorly characterized, but appears to be the main step in the activation of the receptor complex. Extending the HDX analyses to resting and Rap-activated receptor complexes could be a first step to address this question. I tried to come up with an experimental plan to test if indeed the kinase activity of BAK1 and not of EFR is essential for signal propagation, but this is a complex issue. You would need to be able to mimic an activated form of EFR (which you can), to make sure its inactive (possibly, see above) and likewise to engineer a catalytically inactive form of BAK1 in an active-like state (difficult). As such a decisive experiment is difficult to implement, I would suggest to discuss different possible interpretations of the existing data and alternative scenarios in the discussion section of the manuscript.

We addressed your concern whether BAK1 kinase activity is essential for signaling propagation by pairing EFRF761H and BAK1D416N (Figure 4 Supplement 2 C) which fails to induce signaling. In this case, EFRF761H is in its activated conformation but cannot activate downstream signaling. We also attempted to address your concern by an in vitro kinase assay by pairing EFR and BAK1D416N and using a range of concentrations of the substrate BIK1D202N. We observed that catalytic activity of BAK1 but not EFR was essential for BIK1 phosphorylation. However, this experiment does not address whether activated EFR can efficiently propagate signaling in the absence of BAK1 catalytic activity. In the limitations of the study section, we now discuss the catalytic importance of EFR for signaling activation.

Author response image 1.

BIK1 trans-phosphorylation depends on BAK1 catalytic activity. Increasing concentrations of BIK1 D202N were used as substrate for Rap-induced dimers of EFR-BAK1, EFR D849N-BAK1, and EFR-BAK1 D416N respectively. BIK1 trans-phosphorylation depended on the catalytic activity of BAK1. Proteins were purified from E. coli λPP cells. Three experiments yielded similar results of which a representative is shown here.



Reviewer #2:

All of my suggestions are minor.

Figure 1B, I think it would be more useful to readers to explain the amino acid in the D-N change, rather than just call it D-to-N? Also, please label the bands on the stained gel; the shift on FKBP-BRI1 and FKBP-EFR are noticeable on the Coomassie stain.

We implemented your suggestions.

Figure 1-Supplement 1. There is still a signal in pS612 BAK1 (it states 'also failed to induce BAK1 S612 phosphorylation' in the text, which is not quite correct). Also, could mention the gel shift seen in BAK1, which appears absent in Y836F.

We corrected the text which now states: “To test whether the requirement for Y836 phosphorylation is similar, we immunoprecipitated EFR-GFP and EFRY836F-GFP from mock- or elf18-treated seedlings and probed co-immunoprecipitated BAK1 for S612 phosphorylation. EFRY836F also obstructed the induction of BAK1 S612 phosphorylation (Figure 1 – Supplement 1), indicating that EFRY836F and EFRSSAA impair receptor complex activation.” The gel shift of BAK1 you pointed out was not observed in replications and thus we prefer not to comment on it.

Figure 2 and 3 are full of a, b, c,d's, which I don't understand. Sorry

We used uppercase letters to indicate subpanels and lowercase letters to indicate the results of the statistical testing. In the figure caption, we have clarified that the lowercase letters refer to statistical comparisons.

Figure 2 A. If each point on the x-axis is one amino acid, I think it would again be useful to name the amino acids that the gold or purple or blue colored lines extend through.

Each point stands for a peptide which are sorted by position of their starting amino acid from N-terminus to C-terminus. We now added plots of HDX for individual peptides that correspond to the highlighted region in subpanel A.

Figure Supplement 1 is very small for what it is trying to show, even on the printed page. If this residue were to be phosphorylated, what would happen to the H-bond?

We suppose that VIa-Tyr phosphorylation would break the H-bond and causes displacement of the aC-b4 loop. Recent studies, published after our submission, highlight the importance of this loop for substrate coordination and ATP binding. Thus, phosphorylation of VIa-Tyr and displacing this loop may render the kinase rather unproductive. We have expanded the discussion to include this point.

Figure 2B: Tyr 836 is not present in any of the alignments in Figure 2A. This should be rectified, because the text talks about the similarity to Tyr 156 in PKA.

We have adjusted the alignments such that they now contain the VIa-Tyr residues of EFR and PKA.

Figure 4D. Is there any particular reason that these Blots are so hard to compare or FKBP and BAK1?

We assume it is referred to Figure 4 – Supplement 2 D. FKBP-EFR and FRB-BAK1 both are approximately the size of RubisCo, the most abundant protein in plant protein samples and which overlay the FKBP- and FRB-tagged kinase. Thus, it is difficult to detect these proteins.

Reviewer #3:

(1) The paper reporting the allosteric activation mechanism of EGFR should be cited.

Will be included.

(2)The authors showed that "Rap addition increased BIK1 D202N phosphorylation when the BRI1 or EFR kinase domains were dimerized with BAK1, but no such effect was observed with FLS2". Please explain why FLS2 failed to enhance BIK1 transphosphorylation by Rap treatment?

Even though BIK1 is a reported downstream signaling component of FLS2/BAK1, it might be not the most relevant downstream signaling component and rather related RLCKs, like PBL1, might be better substrates for dimerized FLS2/BAK1. We haven't tested this, however. Alternatively, the purified FLS2 kinase domain might be labile and quickly unfolds even though it was kept on ice until the start of the assay, or the N-terminal FKBP-tag may disrupt function. As the reason for our observation is not clear, we have removed FLS2 in vitro dimerization experiments from the manuscript.

(3) Based solely on the data presented in Figure 1, it can be concluded that EFR's kinase activity is not required to facilitate BIK1 transphosphorylation. Therefore, the title of Figure 1, "EFR Allosterically Activates BAK1," may be inappropriate.

We have changed the figure title to: "EFR facilitates BIK1 trans-phosphorylation by BAK1 non-catalytically."

(4) In Figure 1- Supplement 1, I could not find any bands in anti-GFP and anti-BAK1 pS612 of input. Please redo it.

Indeed, we could not detect protein in the input samples of this experiment. BAK1 S612 phosphorylation is an activation mark and not necessarily expected to be abundant enough

for detection in input samples. EFR-GFP, however, is usually detected in input samples and is reported in Macho et al. 2014 from which manuscript these lines come. Why EFR-GFP is not detected in this set of experiments is unclear but, in our opinion, does not detract from the conclusions drawn since similar amounts of EFR-GFP are pulled-down across all samples.

(5) For Figure 2A, please mark the structure represented by each color directly in the figure.

We have made the suggested change.

(6) Please modify "EFRF761/Y836F and EFRF761H/SSAA restore BIK1 trans-phosphorylation" to "EFRF761H/Y836F and EFRF761H/SSAA restore BIK1 trans-phosphorylation".

Thank you for spotting this. We changed it.

(7) The HDX-MS analysis demonstrated that the EFR (Y836F) mutation inhibits the formation of the active-like conformation. Conversely, the EFR (F761H) mutation serves as a potent intragenic suppressor, significantly stabilizing the active-like conformation. Confirming through HDX-MS conformational testing that the EFR (Y836F F761H) double mutation does not hinder the formation of the active-like EFR kinase conformation would greatly strengthen the conclusions of the article.

Response: We agree that this is beneficial, and we attempted to do it but failed to produce enough protein for HDX-MS analysis. We stated this now in an extra section of the paper ("Limitations of the study").